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Abstract 
Polymorphism, which is exhibited in more than half of the active pharmaceutical ingredients, 
has a direct impact on the stability, bioavailability and processability of the product. Despite 
extensive studies on polymorphism in the field of crystal engineering, the control of 
polymorphism is still one of the most challenging tasks in pharmaceutical manufacturing.  
The aim of this work is to crystallize the desired polymorph with the help of process modeling 
and process analytical technologies. First, we investigated the crystallization properties of 
imatinib mesylate, including polymorphism characterization, solubility measurement, 
polymorphic transformation and kinetic parameter estimation, as they are the fundamental 
information for the model-based process design and control of crystallization process and were 
lacking in the literature. Subsequently, the capability of in-situ Raman spectroscopy in 
measuring solution concentration and solids concentration was proved. The analytical models 
were developed with several pre-processing methods and multivariable analysis techniques 
and compared based on the root mean squared errors. Thereafter, the impacts of relative 
kinetics of the two polymorphs on the polymorphic outcome were studied numerically in batch 
and MSMPR (mixed suspension and mixed product removal) crystallizers. The optimal 
operating conditions for harvesting the desired polymorph were analyzed in both modes of 
operations. Lastly, the effects of the operating conditions in batch and MSMPR crystallization 
on the product polymorphism, process yield, and crystal size were investigated. The 
effectiveness of continuous seeding strategy in altering the steady-state condition of MSMPR 
crystallization and its implementation was also proved and discussed. 
In conclusion, this work is concerned with studying the polymorphism phenomenon in 
crystallization processes experimentally and numerically, providing insights into the design, 
optimization and control of batch and continuous crystallization processes. 
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Summary for Lay Audience 
Crystallization is the process by which the atoms or molecules form solid crystals from a 
saturated solution or a gas phase. In the pharmaceutical industry, more than 90% of small 
molecular drugs are delivered in crystalline form and over 80% drug products involve at least 
one crystallization step. The operation conditions during the crystallization process have 
significant effects on the product properties, such as crystal size distribution, purity and 
polymorphism. Polymorphism, which is exhibited in more than half of the active 
pharmaceutical ingredients, refers to the different arrangements of molecules in solid-state and 
has a direct impact on the stability, bioavailability and processability of the drug products. 
Despite extensive studies on polymorphism in the field of crystal engineering, the control of 
polymorphism is still one of the most challenging tasks in pharmaceutical manufacturing.  
This work is concerned with studying the polymorphism phenomenon in crystallization 
processes experimentally and numerically, providing insights into the process design and 
optimization. At first, the investigation of the imatinib mesylate properties, was conducted 
experimentally and thoroughly, in the aspects of characterization, solubility, polymorphic 
transformation, and nucleation and growth rates. These properties are the fundamental and 
necessary information for the process design and control. Then, Raman spectroscopy, a process 
analytic technology, was applied for in-situ monitoring of the solution concentration and slurry 
density of each polymorph during the crystallization process. Subsequently, the impact of 
relative kinetics of the two polymorphs on the polymorphic outcome was studied numerically 
in batch and MSMPR (mixed suspension and mixed product removal) crystallizers. The 
optimal operating conditions for harvesting the desired polymorph were investigated in both 
modes of operations. The influence of each manipulated variable on the crystal properties was 
also studied. 
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1 Introduction 
1.1 Background 
1.1.1 Crystallization 
Crystallization is one of the oldest separation and purification unit operations in the food, 
chemical, biochemical, and pharmaceutical industries (A. S. Myerson, 2002). Specifically, 
in the pharmaceutical industry, the properties of the active pharmaceutical ingredients 
(APIs) are often controlled by the final crystallization step, since over 90% of the small 
molecule drugs exist in crystalline form (Alvarez and Myerson, 2010; Variankaval et al., 
2008). During the crystallization process, the atoms or molecules are transferred from 
solution to the solid phase and form solid crystals.  
Supersaturation, referring to the ratio of actual concertation and solubility at a given 
temperature, is the driving force for the crystallization process. Cooling, evaporation, 
addition of anti-solvent, and chemical reaction can be used to create the supersaturation.  
Usually, the crystallization process consists of two major steps: nucleation and growth. The 
former creates nuclei that are the tiny crystalline phase formed in a supersaturated solution 
or a supercooled liquid and serve as the core in the crystallization process. The latter 
indicates the increase in the particle size and leads to larger crystals.  
Primary nucleation and secondary nucleation are the two main types of nucleation. The 
difference between them is whether the crystals/seeds exist in the supersaturated solution 
when nucleation happens. The control of primary nucleation is hard since it requires high 
supersaturation for phase transition and causes explosive nucleation, resulting in excessive 
small crystals. As a result, primary nucleation is not desired in industry. The control of 
secondary nucleation is widely used since it operates moderately in the metastable zone，
the region between the solubility and supersolubility curve. 
1.1.2 Polymorphism 
Polymorphism refers to the ability of a molecule to crystallize in more than one crystal 
structure with different packing arrangements and/or conformations. It has been reported 
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that more than half of the active pharmaceutical ingredients (API) exhibit solid-state 
polymorphism (Stahly, 2007). Due to the differences in their intra- and intermolecular 
solid-state structures, polymorphic forms of a drug have different chemical and physical 
properties, including melting point, solubility, mechanical properties, and bulk density. 
These properties have a direct impact on the stability and bioavailability of pharmaceutical 
products (Lee et al., 2011), as well as the processability in the downstream processes, such 
as filtration, drying, and tableting.  
In fact, the emphasis on polymorphism in the pharmaceutical industry originates from 
several high-profile disasters in the past decades. Take the example of Ritonavir, which is 
an antiretroviral medication used to treat HIV/AIDS. Only one polymorph was found and 
introduced to the market in 1996. However, after two years, a more stable and not 
therapeutically effective polymorph appeared. The new form compromised the oral 
bioavailability of the drug. Thus, Abbott Company had to withdraw the original capsules 
from the market and caused a loss of 250 million dollars (Qu et al., 2009) 
The occurrence of polymorphism transition in the manufacturing process or transportation 
and storage can lead to the economic loss, more importantly, the legal and health issues. 
Hence, all pharmaceutical companies are required to perform thorough polymorphic 
studies/screening before submitting a New Drug Application by Food and Drug 
Administration (FDA) and other agencies that monitor the production and distribution of 
the drug (Raw et al., 2004).  
Based on the relative stability of two polymorphs, the relationship between them can be 
either monotropic or enantiotropic. For monotropic systems, one form has lower solubility, 
lower Gibbs free energy, and higher thermodynamic stability than the other at all 
temperatures below the melting point. Whereas, for enantiotropic systems, there exists a 
transition temperature, and at that point, the Gibbs free energies of two forms are the same. 
The more stable form depends on what the temperature is, as shown in Figure 1-1. The 
polymorphism transformation from the metastable to the stable form can occur in either 
solid state or solutions, called solid state polymorphic transformation (SST) and solution-
mediated polymorphic transformation (SMPT) (Mullin, 2001).  
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Figure 1-1. Enantiotropic and monotropic polymorphs 
1.1.3 Characterization  
As mentioned above, polymorphism refers to the different crystalline forms of the same 
chemical compound, which have different physical and chemical properties, including 
thermodynamic and spectroscopic properties. These dissimilarities in solid properties can 
be employed as tools for analyzing the solid forms during or after the crystallization process, 
granulation, drying and tableting to meet the regulatory and quality criteria. 
1.1.3.1 Solubility measurement 
Solubility measurement is a strong tool for the study of the stability and transition point of 
polymorphic systems. The most stable polymorph has the lowest solubility at a given 
temperature. Additionally, solubility data is the most fundamental information required to 
design a crystallization process. 
Several techniques have been developed for accurate solubility measurement. Among them, 
the gravimetric method (Zhang et al., 2010) is the most traditional one. In this method, the 
solution with excess solids should be agitated at a constant temperature for a long time to 
reach the thermodynamic equilibrium, followed by filtration. Then the filtrate is weighed 
and placed in an oven to evaporate the solvent. After weighing the residual solid, the 
solubility at the corresponding temperature, 𝑇, can be calculated.  
High-performance liquid chromatography (HPLC) (Li et al., 2016) and ultraviolet/visible 
spectrophotometer (UV/vis) (Mondal et al., 2017),  are also widely used to measure the 
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solubility. Similar to the gravimetric method, the suspension should be agitated and reach 
equilibrium, before being withdrawn and filtered. Then the concentration of the original or 
diluted filtrate is detected with HPLC or UV-Vis spectrophotometer. 
With the off-line methods mentioned above, the samples have to be taken out from the 
crystallizer, followed by one or more steps of drying, filtration, dilution, which is time-
consuming and subject to human and system errors. The in-situ attenuated total reflectance 
Fourier transform infrared (ATR- FTIR) spectroscopy (Yang et al., 2008) and conductivity 
meter  (Garcia et al., 1999) can measure the solution concentration online, so that they are 
more convenient and accurate 
1.1.3.2 Differential Scanning Calorimetry (DSC) 
DSC is the most popular thermal method for pharmaceutical analysis. It measures the 
required heat flow for keeping the temperature of the sample and an empty reference 
crucible the same. DSC provides thermodynamic data, including glass transition 
temperature, melting point and heat of fusion. 
1.1.3.3 Thermal Gravimetric Analysis (TGA) 
TGA measures the weight changes of a sample as a function of temperature. It is therefore 
valuable for cases that are accompanied by weight loss due to heating. Sublimation, 
desolvation and decomposition processes are accompanied by weight changes, so they can 
be identified by this method qualitatively and quantitatively. In contrast, solid-solid and 
solid-liquid transformations are not accompanied by weight loss, so TGA cannot detect 
them. Combined DSC and TGA present valuable information on thermodynamic data, 
polymorphic and pseudo-polymorphic states of pharmaceutical solids.   
In both DSC and TGA, sample size and heating rate influence the results and may lead to 
misinterpretation. A lower heating rate results in obtaining thermodynamic equilibrium, 
while a high heating rate will introduce kinetic factors. A smaller sample size also allows 
faster and more uniform heat transfer to the solid.  
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1.1.3.4 X-ray Powder Diffraction (XRPD) 
XRPD is a powerful method for distinguishing and identifying polymorphs as it is based 
on the structural differences of the crystals. When incident X-ray beams to the crystal, it 
will be reflected only when the angle between the ray and the plane in the crystal matches 
the Bragg equation: 
 𝑛𝜆 = 2𝑑 sin 𝜃 (1-1) 
where 𝜆 is the wavelength of the ray,  
       d is the distance between the planes in the crystal,  
       𝜃 is the angle between the ray and the plane  
       n is the order of the reflection 
1.1.3.5 Raman spectroscopy 
Raman spectroscopy is widely used to monitor the solid phase in crystallization process, 
as it can provide the structural fingerprint based on the scattered light from matter. There 
are two types of scattering: elastic and inelastic (Staveley, 2016). In elastic scattering, also 
called Rayleigh scattering, the molecule is excited to a new state followed by relaxation to 
the original state, re-emitting a photon at the same frequency as the incident light. In 
inelastic scattering, also called Raman scattering, the excited molecules relax to a different 
vibrational state, emitting photons with a different energy than the incident light.  
 
Figure 1-2. Raman scattering 
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Only a small fraction of molecules undergoes inelastic scattering, so the Raman scattering 
intensity will be overwhelmed by the reflected incident light. To improve the signal to 
noise ratio, a high-power laser beam is focused to the focal point to enhance the occurrence 
of Raman scattering. The spectrometer employs groups of optical elements to filter and 
amplify the signal with different wavelength than the incident light caused by Raman 
scattering (Figure 1-3). The cooled image sensor captures each spectrum with a long 
exposure to accumulate signal. The high-sensitivity setup enables the Raman spectroscopy 
a perfect tool to monitor the concentrations of both solids and liquid phase as well as 
detecting the polymorphic transformation of the crystals. 
 
Figure 1-3. Schematics of a Raman spectroscopy meter 
1.1.3.6 Focused Beam Reflection Measurement (FBRM)  
The FBRM uses a confocal laser beam that scans across the surface of the particles passing 
in front of the probe’s sapphire window to measure the chord length distribution (CLD). 
As shown in Figure 1-4, the rotary optical lens drives the laser beam rotating at a constant 
speed (2 m/s). When the laser beam hits the crystals near the focal point, the backscattering 
light is detected, and the durations are converted to the chord length. The confocal 
mechanism ensures a limited depth of field (DOF), i.e., the crystals far from the laser focal 
point will not be detected. This helps to resolve the overlapping crystals in different depths 
when the solids concentration gets high. The chord length depends on the characteristic 
length, the shape, the surface roughness, the optical properties, and the velocity of the 
crystals. The chord length tends to underestimate the size of the crystal because of the high 
probability of scanning shorter chords than the full characteristic length of a crystal. 
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Figure 1-4. FBRM mechanism 
FBRM has been extensively used to monitor nucleation event, controlling the crystal 
number density with direct nucleation control (Saleemi et al., 2012a), and extract aspect 
ratio and more accurate size distribution with fine-tuned algorithms (Borsos et al., 2017). 
Its easy-to-use probe design and the ability to work in relatively high solids concentration 
make it a well-received process analysis technology in both industry and research. 
1.1.4 Population balance equation  
Besides polymorphism, crystal size distribution (CSD) is another significant property of 
pharmaceutical products, as CSD influences greatly the downstream processes (e.g. 
filtration, drying, and tableting) and the product performances (Abu Bakar et al., 2009). 
Population balance equation (PBE) is widely used to describe the crystal size with respect 
to time and space in both academic and industrial research (Nagy et al., 2013a).PBE was 
first proposed by Hulburt and Katz (Hulburt and Katz, 1964) and applied in the 
crystallization process by Randolph and Larson (Randolph and Larson, 1971). The 
analytical solutions of PBE were extensively studied by Ramkrishna (Ramkrishna, 2000). 
Due to the existence of aggregation and breakage, the analytical solutions of PBE do not 
exist unless some assumptions are applied. So often numerical methods are employed for 
solving PBE. A comprehensive review of the solution methods of PBE was carried out by 
Omar and Rohani (Omar and Rohani, 2017).  
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PBE can be obtained with the Lagrangian or Eulerian approach (Equation (1-2) and (1-3)). 
The Lagrangian viewpoint tracks a subregion of particle size (𝐿𝑖—𝐿𝑖+1) in a flow system, 
while Eulerian viewpoint tracks a volume V of external phase space (Randolph and Larson, 
1971).  
 
𝜕𝑛
𝜕𝑡
+ 𝛻. (𝒗𝒆𝑛) + 𝛻. (𝒗𝒊𝑛) = 𝐵 − 𝐷 (1-2) 
 
𝜕𝑛
𝜕𝑡
+ 𝛻. (𝒗𝒊𝑛) + 𝑛
𝑑(𝑙𝑜𝑔𝑉)
𝑑𝑡
= 𝐵 − 𝐷 − ∑
𝑄𝑘𝑛𝑘
𝑉
𝑘
 (1-3) 
where 𝑛 is population density, 𝒗𝒆 is external velocity vector, 𝒗𝒊 is the internal velocity 
vector, B is crystal birth rate, D is the crystal death rate. V is the crystallizer volume, and 
𝑄𝑘𝑛𝑘  is the volumetric inflow/outflow multiplied by the number density of the 
inflow/outflow streams. Usually, the particle velocity is assumed to be equal to the liquid 
velocity. A commonly used one-dimensional PBE  
 
𝜕𝑛
𝜕𝑡
+
𝜕(𝐺𝑛)
𝜕𝐿
= 𝐵 − 𝐷 (1-4) 
The birth term represents the new crystals produced from nucleation, aggregation and 
breakage processes, while the death term presents the particle disappearance due to the 
dissolution, aggregation and breakage (Bhoi and Sarkar, 2016). The common expression 
for the birth and death rates are shown in Figure 1-5, where 𝑏(𝑡, 𝑥, 𝑥′) is the probability 
density function for the generation of particles, 𝑎(𝑥) and 𝑎(𝑥′) are the break rates of the 
particles with size 𝑥 and 𝑥′, and  𝛽(𝑡, 𝑥 − 𝑥′, 𝑥′) is the frequency of collisions between 
crystals with size 𝑥 − 𝑥′ and 𝑥′ (Qamar et al., 2009).  
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Figure 1-5. Formulation of birth and growth rates 
1.1.4.1 Analytical Solution  
The most common analytical solution of PBE is derived from mixed suspension mixed 
product removal crystallizers (MSMPR), with the assumption that a crystallizer has a 
uniform distribution of suspended solids and negligible breakage and agglomeration (A. 
Myerson, 2002). If the feed of MSMPR is a clear solution without crystals (i.e., 𝑛𝑖 = 0), 
and growth rate is size-independent, the PBE for the steady-state MSMPR will be  
 𝐺
𝜕𝑛
𝜕𝐿
+
𝑛
𝜏
= 0 (1-5) 
where 𝐺 is the growth rate,  𝐿 is crystal size, and 𝜏 is residence time.  
The solution of Equation (1-5)  is  
 𝑙𝑛 𝑛 = −
1
𝐺𝜏
∗ 𝐿 + 𝑙𝑛 𝑛0 (1-6) 
where 𝑛0 is the population density of zero-sized crystals. From the definition of nucleation, 
one can get  
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 𝑛0 =  (
𝑑𝑁
𝑑𝐿
)𝐿→0 = (
𝑑𝑁
𝑑𝑡
/
𝑑𝐿
𝑑𝑡
)𝐿→0 =
𝐵
𝐺
 (1-7) 
From Equation (1-6) and (1-7), it is known that the slope and intercept of the “ln 𝑛 vs. 𝐿” 
curve are −
1
𝐺𝜏
 and 𝑙𝑛 (
𝐵
𝐺
). Therefore, the analytical solution of MSMPR can be used as one 
approach for determining the nucleation and growth rates. 
1.1.4.2 Numerical methods 
As mentioned above, the analytical solutions exist only for some limited simplified cases, 
so much effort has been invested to numerically solve these equations. There are several 
numerical methods to solve PBE, such as the method of moments (Hulburt and Katz, 1964; 
Randolph and Larson, 1971; Ramkrishna, 2000), method of classes (Hounslow et al., 1988; 
Marchal et al., 1988), finite element method (Tsang and Rao, 1990; Nicmanis and 
Hounslow, 1998; John et al., 2009), finite volume method (Gunawan et al., 2004a; Szilágyi 
et al., 2019)  and Monte Carlo method (Smith and Matsoukas, 1998; Tandon and Rosner, 
1999; Bárkányi et al., 2013).  
1.1.4.2.1 Method of moments 
The method of moments converts the PBE into ordinary differential equations in terms of 
moments of the number density. The moments are defined as  
 𝑚𝑗(𝑡) = ∫ 𝐿
𝑗𝑛(𝐿, 𝑡)𝑑𝐿
∞
0
 (1-8) 
where 𝑚𝑗 is the jth moment. Substituting Equation (1-8) into Equation (1-2) results in 
𝜕𝑚𝑗
𝜕𝑡
− 0𝑗𝐵(𝑡) − 𝑗 ∫ 𝐿𝑗−1(𝑡)𝑛(𝐿, 𝑡)𝐺(𝐿, 𝑡)𝑑𝐿
∞
0
= ∫ (𝐵 − 𝐷)𝑑𝐿
∞
0
 (1-9) 
With negligible breakage and size-independent growth rate, Eq. (1-9) can be simplified to 
 
𝑑𝑚𝑗(𝑡)
𝑑𝑡
= 0𝑗𝐵(𝑡) + 𝑗𝐺(𝑡)𝑚𝑗−1(𝑡) (1-10) 
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The zeroth to third moments correspond to the total number, total length, total area and 
total volume of all particles that can be measured by focused beam reflectance 
measurement (FBRM). The average crystal size can be obtained from
𝑚𝑗
𝑚𝑗−1
. 
The advantage of MOM is that the computational process is relatively simple compared to 
other methods. The main drawback is that it cannot generate the crystal size distribution 
(Abbas and Romagnoli, 2007) and it does not work when the kinetic rate is non-linear and 
size-dependent (Sheikholeslamzadeh, 2013). 
1.1.4.2.2 Method of characteristics 
The method of characteristics can convert a partial differential equation to a set of ordinary 
differential equations along the characteristic length. In the case of the population balance 
equation in crystallization process, the crystal size 𝐿 is gridded into finite bins, and Eq. 
(1-4) can be transformed into a finite set of ODEs in terms of particle number density (or 
particle number) in each size bin, as shown in Eq. (1-11) 
𝜕𝑛(𝑡, 𝐿)
𝜕𝑡
=
𝐺𝑗−1𝑁𝑗−1 − 𝐺𝑗𝑁𝑗
∆𝐿
+
𝐷𝑗+1𝑁𝑗−1 − 𝐷𝑗𝑁𝑗
∆𝐿
 (1-11) 
where ∆𝐿  is the spatial step. Compared to the method of moment, the method of 
characteristics is more advance in the aspect of preserving the crystal size distribution, but 
it is much more computationally expensive, especially when solving complex systems with 
small crystal size bins (Lim et al., 2002). The combined method of moments and method 
of characteristics can solve the PBE accurately with reduced computational cost (Aamir et 
al., 2009).  
1.1.4.2.3 High-resolution finite volume method 
High-resolution methods were developed for solving the nonlinear hyperbolic equation, 
which is common in engineering applications as it describes the dynamics of material, 
energy, momentum, and population balances (Gunawan et al., 2004b).  
 
𝜕𝑛
𝜕𝑡
+ 𝐺
𝜕𝑛
𝜕𝐿
= 0 (1-12) 
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Eq. (1-12) is a simplified population balance equation with a size-independent growth rate 
(𝐺 > 0). Numerical difficulties arise when the spatial derivative 
𝜕𝑛
𝜕𝐿
 is very large. For 
example, the nucleation events can create a significant peak of 𝑛 at the smallest size grid, 
leading to a large spatial gradient. Despite the numerical stability, the first-order methods 
(e.g., upwind scheme) tend to produce numerical diffusion, where the solution is smeared 
or damped (Figure 1-6 a). The second-order methods (e.g., Lax-Wendroff scheme) 
introduce numerical dispersion where the local spatial derivative is large, causing 
nonphysical oscillations in the solutions (Figure 1-6 b) (Morton and Mayers, 1994).  
 
Figure 1-6. Demonstration of numerical diffusion and dispersion in first-order and 
second-order methods 
The high-resolution (HR) methods are designed to leverage both the stability of the first-
order methods near the discontinuity and the accuracy and shape-preservation of the 
second-order methods where the solution is smooth. Modern high-resolution methods are 
derived from the integral representation for the underlying conservation equations, so they 
are categorized as finite volume methods (FVMs). This implies the conservation of the 
interested properties and the accurate simulation of the growth rate kinetics without further 
specialized processes as required by finite difference methods. Discretizing Eq. (1-12) with 
discrete FVM method results in Eq. (1-13) 
 𝑛𝑘
𝑚 = 𝑛𝑘
𝑚−1 + 𝐹(Δ𝑡, Δ𝐿, 𝑛, 𝐺) (1-13) 
where 𝑛𝑘 is the 𝑘-th element of the discretized size distribution; 𝐿𝑘 is the characteristic 
size of the 𝑘 -th discretized channel; Δ𝐿  and Δ𝑡  are the spatial and time step size, 
(a) Upwind scheme (b) Lax-Wendroff scheme 
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respectively; 𝐹 is the spatial discretization function that can be computed with low-order 
(upwind scheme) or high-order (Lax-Wendroff scheme) methods (Eq.(1-14)). 
𝐹 = {
− 
𝐺Δ𝑡
Δ𝐿
(𝑛𝑘
𝑚−1 − 𝑛𝑘−1
𝑚−1), Upwind (𝐹𝑙𝑜𝑤)
−
𝐺Δ𝑡
2Δ𝐿
(𝑛𝑘+1
𝑚−1 − 𝑛𝑘−1
𝑚−1) −
(𝐺Δ𝑡)2
2Δ𝐿2
(2𝑛𝑘
𝑚−1 − 𝑛𝑘−1
𝑚−1 − 𝑛𝑘+1
𝑚−1), Lax-Wendroff (𝐹ℎ𝑖𝑔ℎ)
 
  (1-14) 
In high-resolution finite volume methods (HRFVM), the spatial discretization function can 
switch between the schemes depending on the local derivative of the size distribution with 
a flux limiter, 𝜙(𝜃). The combined function becomes Eq. (1-15). When 𝜙 → 0, the local 
derivative is large, it weighs more on the low-order scheme to improve stability (𝐹𝐻𝑅 =
𝐹𝑙𝑜𝑤).  When 𝜙 ≥ 1, the local derivative is small, so the high-order scheme is emphasized 
to improve accuracy. Since 𝜙 is a continuous function, the weights on low-order and high-
order schemes are continuously adjusted. 
 𝐹𝐻𝑅 = 𝐹𝑙𝑜ß𝑤 − 𝜙(𝜃)(𝐹𝑙𝑜𝑤 − 𝐹ℎ𝑖𝑔ℎ)  (1-15) 
The flux limiter selectively weighs on low-order and high-order methods depending on the 
local degree of smoothness (𝜃) of the size distribution (Eq. (1-17)). In the corner cases 
when the denominator is zero, 𝜃𝑘 is set to zero; if both numerator and denominator are zero, 
𝜃𝑘 is set to 2 (Rajagopalan et al., 2015). 
 𝜃𝑘 =
𝑛𝑘 − 𝑛𝑘−1
𝑛𝑘+1 − 𝑛𝑘
 (1-16) 
Many flux limiters have been proposed, with each one leading to a different high-resolution 
method. The Van Leer limiter (Eq. (1-17)) provides full second-order accuracy and is 
proven to work well in the population balance equations. 
 𝜙(𝜃𝑘) =
𝜃𝑘 + |𝜃𝑘|
1 + |𝜃𝑘|
 (1-17) 
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Figure 1-7 demonstrates the Van Leer flux limiter versus local smoothness, 𝜃.  When 𝜃 <
0, the local derivative crosses zero, prompting an aggressive local gradient. Therefore, 𝜙 
is capped to zero to switch the low-order method for stability. When 𝜃 > 0, the increasing 
𝜃 indicates the trend of the size distribution is getting flatter, i.e., the absolute derivative is 
getting smaller. In this case, 𝜙  increases monotonically with 𝜃  so that the high-order 
scheme starts to play more significantly. 
 
Figure 1-7. Van Leer flux limiter 
In this algorithm, the computation of 𝑛𝑘
𝑚+1 depends on the values of 𝑛𝑘−2
𝑚 . It is common 
to assume that these virtual channels to be zero (Gunawan et al., 2004b). When primary 
and secondary nucleation kinetics are considered, the new-born particles are added to the 
first channel 
 𝑛1
𝑚 = 𝑛1
𝑚 + 𝐵
Δ𝑡
Δ𝐿
 (1-18) 
where 𝑛1 is the number density in the first channel; and 𝐵 is the combined primary and 
secondary nucleation rate [𝑠−1 ⋅ 𝑚−3] (Rajagopalan et al., 2015). 
𝑛𝑘
𝑚+1 = 𝑛𝑘
𝑚 −
𝐺Δ𝑡
Δ𝐿
[𝑛𝑘
𝑚 − 𝑛𝑘−1
𝑚 ] −
𝐺Δ𝑡
2Δ𝐿
(1 −
𝐺Δ𝑡
Δ𝐿
) [(𝑛𝑘+1
𝑚 − 𝑛𝑘
𝑚)𝜙𝑘 − (𝑛𝑘
𝑚 − 𝑛𝑘−1
𝑚 )𝜙𝑘−1]   
  (1-19) 
𝑛𝑘
𝑚+1 = 𝑛𝑘
𝑚 +
𝐺Δ𝑡
Δ𝐿
[𝑛𝑘
𝑚 − 𝑛𝑘+1
𝑚 ] +
𝐺Δ𝑡
2Δ𝐿
(1 +
𝐺Δ𝑡
Δ𝐿
) [(𝑛𝑘−1
𝑚 − 𝑛𝑘
𝑚)𝜙𝑘 − (𝑛𝑘
𝑚 − 𝑛𝑘+1
𝑚 )𝜙𝑘+1]     
16 
 
  (1-20) 
In summary, the HRFVM discretization of the population balance equation is formulated 
as Eq. (1-19)  for growth (𝐺 > 0) and Eq. (1-20) for dissolution (𝐺 < 0). Practically, given 
the arbitrary spatial step size Δ𝐿, the time step size Δ𝑡 can be determined with the Courant-
Friedrichs-Levy (CFL) condition as in Eq. (1-21) (Gunawan et al., 2004b). By using a 
smaller 𝛼, the time step is divided finer, and the result is more accurate at the cost of 
computational time, and vice versa. 
 |
𝐺Δ𝑡
Δ𝐿
| = 𝛼 ≤ 1 (1-21) 
Figure 1-8 depicts the solution computed with the HRFVM algorithm. Compared to the 
pure upwind and Lax-Wendroff schemes, the HRFVM is showing minimum numerical 
dispersion and diffusion, prompting it as an effective approach to numerically solve the 
population balance equations. 
 
Figure 1-8. Demonstration of HRFVM solution 
1.1.5 Control of crystallization processes 
Crystallization process control is gaining increasing attention and popularity in industry 
and academic research. Various applications have shown the potentials of crystallization 
controls including controlling the bioavailability of active pharmaceutical ingredients 
(APIs), improving the purity of solids products, ensuring the polymorphic stability of 
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crystals for shelf life, and adjusting the size and shape of the crystals for better downstream 
processability (Nagy et al., 2013b).  
In 2004, The United States Food and Drug Administration (FDA) introduced guidance 
related to the concept of quality-by-design (QbD) and the use of process analytical 
technology (PAT) for manufacturing pharmaceutical products (U.S. Food and Drug 
Administration/Department of Health and Human Services, 2004). The QbD is based on 
the understanding of the crystallization processes using experiments and modeling 
techniques to archive the desired product specification and minimize the variability in the 
product quality. Thirunahari et al. implemented the QbD-based crystallization of 
tolbutamide with the aid of in-situ PATs to screen the desired polymorph of the products 
for better downstream processability (Thirunahari et al., 2011). Tulcidas et al. studied the 
mixing condition in an anti-solvent crystallization process under the framework of QbD to 
minimize the failure and out-of-specification batches (Tulcidas et al., 2019). 
The strategy of quality-by-control (QbC) was developed to complement the QbD, which 
encourages using feedback control approaches to determine operating trajectories instead 
of following the predefined optimal operating conditions found in the design stage. The 
tuned feedback control can reduce the impacts of disturbances and further reduce the 
product variations and therefore improve the process robustness (Yang et al., 2015). The 
recent development of online PAT tools enables the effective feedback control and the 
implementations of QbC concept in crystallization processes (Acevedo et al., 2016; Ma 
and Wang, 2012; Nagy et al., 2013c). The control of crystal size distribution (CSD) is 
particularly important since it has a significant impact on the efficiency of downstream 
operations, where typically large and uniform crystals are desired, whereas fine or broadly 
distributed particles can cause problems during the filtration and drying processes. 
However, the control of CSD is still a challenging task because of the stochastic nature of 
nucleation and the limit and precision of the online PAT tools (Yang et al., 2015).  
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Figure 1-9. Crystallization process control techniques (Nagy et al., 2013c) 
Various control approaches have been proposed to solve this challenge and control CSD in 
a crystallization process, which can be categorized into model-based and model-free 
control strategies (Figure 1-9). Model-based control strategies emerged since the 
pioneering works by Mullin ((Jones and Mullin, 1974; Mullin and Nývlt, 1971)), which 
showed the advantages of a programmed optimal cooling profile. Since then, major 
progress has been made and enabled the model-based control of various important product 
qualities. The model-based control involves solving the population balance model (PBM) 
iteratively to optimize the product qualities (e.g., CSD and polymorphism) subject to a set 
of constraints due to equipment limitations (e.g. temperature range, cooling rates limit,  
antisolvent addition rate limit, etc.) as well as the productivity constraint that ensures the 
desired yield at the end of the batch (Corriou and Rohani, 2008).  Computational fluid 
dynamics (CFD) is an auxiliary method for analyzing the flow fields along with the PBM. 
This is a helpful tool to associate the different geometries and operations of the crystallizers 
to the temperature and the concentration profiles. The major advantage of the model-based 
control is the smaller number of experiments required for identifying the system due to the 
theoretical modeling techniques. Majumder and Nagy (Majumder and Nagy, 2013) 
predicted the shape distribution of potassium dihydrogen phosphate in the presence of 
additives by solving the PBE in combination of the crystal impurity model. Furthermore, 
a crystallization control strategy was designed for the process based on the proposed model. 
Su et al. (Su et al., 2015)  developed a general and robust mathematical model to transform 
Crystallization 
control 
Model-free 
control 
Model-based 
control 
Linear cooling 
Supersaturation control (SSC) 
Direct nucleation control (DNC) 
Open-loop optimal control 
Model predictive control (MPC) 
19 
 
from a batch operation into a continuous process. A PI (proportional-integral) controller 
was designed to ensure that the start-up and normal operation fell within the same design-
space as the batch operation by maintaining the concentration near the designed optimal 
profile, which demonstrates its ability of generalization and operating against uncertainties.  
Model predictive control (MPC) is a promising model-based control strategy, which 
controls the system by continuously performing optimization in a prediction horizon that 
shifts over time with the model and measured outputs. Yang and Nagy (Yang and Nagy, 
2015) applied a model predictive control to a two-stage MSMPR crystallizer based to 
optimize the CSD and yield by adjusting the temperatures and anti-solvent dosing rate in 
cooling and anti-solvent crystallization. Hermanto et al. (Hermanto et al., 2010) developed 
an MPC for a polymorphic transformation process (L-glutamic acid) to minimize batch-to-
batch variations. The open problems associated with the model-based technique are the 
deficiency of the kinetic models and the assumptions to approximate the CSD due to the 
lack of understanding of the process, which can affect the model accuracy and pose a 
negative impact on the control performance (Nagy and Braatz, 2012). 
Model-free control strategies involve the direct use of online measurements and are widely 
used because of their simplicity, which has been applied in the control of CSD, crystal 
shape, and polymorph (Powell et al., 2015). Figure 1-9 lists several widely used model-
free control approaches. The linear cooling is a simple strategy that is usually used when 
exploring the crystallization process, so they are often discussed separately from the other 
novel techniques. Supersaturation control (SSC) is based on the theory to control the 
crystallization process by adjusting the temperature or antisolvent addition to maintain the 
supersaturation constant or optimal to maintain minimal unwanted nucleation while 
keeping high growth rate to ensure high productivity (Hansen et al., 2017). Often this 
strategy can result in close to optimal crystallization performance after only a few 
experiments (Nagy et al., 2013c). Direct nucleation control (DNC) is a novel model-free 
control that directly measures the particle counts with online PATs (e.g., FBRM) and 
removes fine particles by rapid switching between heating and cooling or solvent or 
antisolvent addition strategies. The advantages of the DNC have been verified for 
producing the crystals with a desired mean size (Saleemi et al., 2012b) or polymorphic 
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form (Bakar et al., 2009). Kacker et al. (Kacker et al., 2016) used microwave heating to 
eliminate the limitations of heat transfer caused by the traditional approaches, which 
resulted in a fast fine-removal response during DNC applications and significantly reduced 
the batch time. Yang et al. (Yang et al., 2015) proposed a DNC to reduce the startup time 
required for a continuous crystallization process by quickly nucleating the desired number 
of crystals under the monitoring of FBRM. They further investigate adopting the wet 
milling in a single-stage MSMPR system to facilitate nucleation and startup process (Yang 
et al., 2016).  
Whether a model-based or a model-free control strategy is used, the crystallization kinetics 
and particle density in the system are always closely related to the product quality and 
productivity. For some simple systems that are fully described by a simple nucleation and 
growth models, the model-based control approach has the ability to exploit the optimal 
crystallization process and provides a safe process operation. On the other hand, for the 
systems that are prone to aggregation and breakage or demonstrating special phenomena 
that is difficult to describe in models (e.g., oiling-out), the model-free control has higher 
accuracy and flexibility. With the deepening understanding of the crystallization 
mechanism and rapid development of the online PAT tools, one can foresee the strong 
potential of the hybrid control strategy combining the model-based and model-free control 
strategies. 
1.2 Research objectives and approach 
1.2.1 Research objectives 
Due to the hard-to-predict nature of polymorphism (Ainurofiq et al., 2020; Bernstein, 2008; 
Desiraju, 1997), the control of polymorphism remains challenging in pharmaceutical 
manufacturing. In this work, the main objective is to produce the desired polymorph of 
active pharmaceutical ingredients in crystallization processes based on the study of 
polymorphism phenomenon and process analytic technology. 
The detailed objectives are: 
• Study the thermodynamic and kinetic properties that are fundamental information 
for the crystallization process modeling and control. 
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• Develop a simple analytical method to quantitatively measure the solution 
concentration and slurry density to implement the real-time monitoring of the 
crystallization process. 
• Study the impact of polymorph relative kinetics of a bi-polymorphic system on the 
polymorphic outcome, and provide a general approach to determine the optimal 
crystallization operation to harvest the desired polymorph in batch and continuous 
operation. 
• Study the impacts of operating conditions on the product properties in batch and 
MSMPR crystallization, and offer general guidance for designing a crystallization 
process. 
1.2.2 Research approach 
In chapter 2, the polymorphs of imatinib mesylate were identified with powder X-ray 
diffraction (PXRD). Thermal properties, such as melting point and enthalpy, were 
measured by differential scanning calorimeter (DSC) and thermal gravimetric analysis 
(TGA). Optical microscopy and scanning electron microscopy (SEM) provided the 
morphologic information, and ultraviolet-visible spectroscopy (UV-Vis) was used to 
measure the solubility. The solution concentration and polymorphic composition of the 
solid phase during the solution or solution-mediated polymorphic transformation (SMPT) 
process were monitored by Raman spectroscopy and conductivity meter. The parameter 
estimation was performed with MATLAB optimization function, 𝑓𝑚𝑖𝑛𝑐𝑜𝑛, based on the 
sequential quadratic programming (SQP) method. The population balance equation was 
solved by the method of characteristics and method of moments. 
In chapter 3, the polymorphs of paracetamol and L-Glutamic acid were identified with 
powder X-ray diffraction (PXRD). The dataset was collected with the Simulink program. 
Three pre-processing methods (spectra range selection, baseline removal, direct orthogonal 
signal correction) and four multivariable analysis techniques (characteristic peaks 
regression (CPR), principal component regression (PCR), partial least squares regression 
(PLSR) and artificial neural network (ANN)) were applied to analyze the Raman 
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spectroscopy in MATLAB. Focused Beam Reflectance Method (FBRM) was used to 
monitor the crystal count. 
The simulation of the crystallization process in chapter 4 and chapter 5 was conducted with 
MATLAB. In chapter 4, the population balance equation was solved by the high-resolution 
finite volume method. In chapter 5, the population balance equation was solved by the 
method of characteristics and method of moments. 
1.3 Thesis organization 
This thesis is in the integrated-article format. 
Chapter 1 provides the research background, objectives, approach and thesis structure. 
Chapter 2 presents the experimental study of a polymorphic system, including polymorph 
characterization, solubility measurement, polymorphic transformation, and kinetic 
parameter estimation.  
Chapter 3 discusses the monitoring of the crystallization process of the polymorphic 
systems. The capability of Raman spectroscopy on in-situ measuring the solution 
concentration and slurry density was investigated. 
Chapter 4 studies the impacts of relative kinetics of the two polymorphs on the 
polymorphic outcome numerically in batch and MSMPR crystallizers. The investigation 
of optimal operations for the desired polymorph in both modes of operations is also 
included. 
Chapter 5 reports the effects of the operating conditions in batch and MSMPR 
crystallization on the crystal properties, including the polymorphism, yield and crystal size 
distribution. The intermittent seeding and withdrawal strategy has been proven to alter the 
steady-state conditions and avoid the clogging issue during the suspension transport in 
MSMPR crystallization. 
Chapter 6 consists of the conclusions and recommendations for future works. The Matlab 
codes developed for the process modeling and data analysis are listed in the Appendix.   
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2 A Kinetic Study of Crystallization Process of Imatinib 
Mesylate with Polymorphic Transformation Phenomenon 
Abstract  
For pharmaceutical crystallization design and control, the kinetics of nucleation and growth 
of crystals are significant parameters, especially for the system exhibiting polymorphic 
transformation. In this study, imatinib mesylate, whose solubility, nucleation and growth 
kinetics are lacking in the literature, was thoroughly explored in the aspects of 
characterization, solubility and polymorphic transformation, and evaluation of nucleation 
and growth rate. Two forms of imatinib mesylate, α and 𝛽, were characterized by X-ray 
powder diffraction, scanning electron microscopy and differential scanning calorimetry. 
The solubility measurement of the two forms was performed with ultraviolet–visible 
spectroscopy in three solvents from 278.15 to 333.15 K at atmospheric pressure. The 
results indicated the 𝛽-form is more stable in methanol,1-propanol, and 2-propanol under 
the experimental condition. The solubility order is methanol >1-propanol >2-propanol. The 
solution-mediated polymorphic transformation (SMPT) of imatinib mesylate from 𝛼-form 
to 𝛽-form was studied with the in-situ Raman spectroscopy and conductivity meter. It is 
found that the SMPT process of imatinib mesylate from 𝛼-form to 𝛽-form in methanol is 
controlled by nucleation and growth of 𝛽-form. Finally, the nucleation and grow rate of 𝛽-
form of imatinib mesylate were estimated by minimizing the difference between the 
calculated and experimental solution concentration with MATLAB optimization function. 
2.1 Introduction 
Depending on the arrangement of molecules, a solid can be a crystal, a quasicrystal or an 
amorphous. A phenomenon called polymorphism, exists widely in the crystalline solids, 
especially in organic compounds(Stahly, 2007). Even though polymorphs have the same 
molecular formula, they are different in molecular conformations and/or packing 
arrangements in the solid state, resulting in the distinct physical and chemical properties, 
such as morphology, melting point, flow properties, mechanical properties, solubility, and 
Gibbs free energy(Myerson, 2002). In terms of active pharmaceutical ingredients (API), 
polymorphism would affect the processability, bioavailability and stability of the API(Lee 
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et al., 2011). Therefore, the identification and control of polymorphs of a given API are 
essential for the pharmaceutical industry. 
Comparing with the stable polymorph, the metastable polymorph has higher solubility and 
Gibbs free energy. The divergence in Gibbs energy drives polymorphism to transit from 
the metastable form to the stable state. Generally, there are two ways to realize the 
transition: solid-state polymorphic transformation (SST) and solution-mediated 
polymorphic transformation (SMPT)(Mullin, 2001). The SMPT process consists of three 
steps: dissolution of the metastable form, nucleation of stable form, and growth of stable 
form. The slowest step of the SMPT process limits the whole transition rate. Based on the 
relative rate of dissolution, nucleation, and growth, O’Mahony et al. rationalized the SMPT 
process into four possible scenarios: dissolution-controlled, nucleation-dissolution-
controlled, growth-controlled, nucleation-growth-controlled (O’Mahony et al., 2012).  
In order to model and control a crystallization process, the kinetic parameters, namely 
nucleation rate, growth rate, dissolution rate, agglomeration, and breakage have to be 
determined first through experiments. For the nucleation and growth rate, there are three 
experimental methods commonly used to determine the nucleation and growth rate. The 
first one relies on the crystal size distribution of the final product obtained from a Mixed-
Suspension, Mixed-Product Removal (MSMPR) crystallizer. The slope and intercept of 
the “particle number density vs. crystal size” curve provide the information necessary to 
extract the nucleation and growth rates (Myerson, 2002). The second method which is 
somewhat approximate, is based on the count and chord length distribution measured by 
the Focused Beam Reflectance Measurement (FBRM) device (Trifkovic et al., 2012). The 
change in the count of fine crystals presents the nucleation rate, while the change in 
average chord length refers to the growth rate. The last method uses a rigorous parameter 
estimation algorithm and works by finding a set of proper constants in the kinetic equations 
to minimize the difference between the experimental data (measured solute concentration 
and/or crystal size distribution) and modeling results (Morris et al., 2015). 
The compound studied in this work is imatinib mesylate. Imatinib mesylate (Figure 2-1), 
chemically 4-[(4-methylpiperazin-1-yl) methyl]-N-[4-methyl-3-[(4-pyridin-3-
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ylpyrimidin-2-yl) amino]-phenyl] benzamide methanesulfonate, was developed by 
Novartis under the trade name “Gleevec/Glivec®” in the late1990s. It was designed as a 
protein tyrosine kinase inhibitor and shows a remarkable therapeutic effect in Philadelphia 
chromosome positive chronic myelogenous leukemia (CML) and metastatic malignant 
gastro intestinal stromal tumors (GISTs) (Al-Hadiya et al., 2014). Many polymorphs of 
crystalline imatinib mesylate have been observed by precipitating from a solution that 
consists of an organic solvent, imatinib base and methanesulfonic acid. The different 
solvents lead to different polymorphs of the final product (Amala et al., 2005; Kompella et 
al., 2006; M. Mutz, 2007; Mutz M., 2007; Parthasaradhi et al., 2003; Patel et al., 2006; 
Pathi et al., 2005; Zimmermann et al., 1999). 
Table 2-1. Some patents about polymorphs of imatinib mesylate 
Patent Solvent Polymorph Ref. 
WO 1999/03854 
α: non-alcoholic solvents 
𝛽: a suitable polar solvent, especially alcohol, most or 
also a ketone or mixtures thereof 
Needle α and 
cubic 𝛽 form 
(Zimmermann 
et al., 1999) 
WO 2004/106326 Chlorinated solvents  H1 
(Parthasaradhi 
et al., 2003) 
WO 2005/077933 isopropanol α2 
(Amala et al., 
2005) 
WO 2006/024863 Alcoholic solvents (C2 to C4 alcohols) or ketonic solvents.  
Nonhygroscopic α 
crystalline form  
(Pathi et al., 
2005) 
WO 2006/048890 
 A polar protic or aprotic solvent, a non-polar solvent, 
water or mixture thereof. 
Non-Needle α 
form 
(Kompella et 
al., 2006) 
WO 2006/054314 Chloroform and water  I, II 
(Patel et al., 
2006) 
WO 2007/023182 
δ: acetone and methanol 
ε :ethyl acetate and ethanol 
δ, ε 
(Mutz M., 
2007) 
WO 2007/059963 
F—benzyl Alcohol 
G—a mixture of 3-Pentanone and cyclohexane 
H—a mixture of 3-Pentanone and N.N-
Dimethylformamide 
I—a mixture of Ethyl Acetate and Diethyl Ether 
K—a mixture of Ethyl Acetate and N,N-
Dimethylformamide 
F, G, H, I, K 
(M. Mutz, 
2007) 
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Among the dozens of polymorphs of imatinib mesylate, the α-form and the 𝛽-form 
proposed in WO99/03854 (Zimmermann et al., 1999)  are the most frequent and 
commercialized. The cubic-shaped 𝛽-form has the lower hygroscopic ability, higher flow 
properties, and higher stability at temperatures below 140° C than the needle-shaped α-
form, as summary in Table 2-2. Therefore, the 𝛽-form shows better performance than α-
form in terms of processability, manufacturing, pharmaceutical preparation, and storage 
(Zimmermann et al., 2005). 
 
Figure 2-1. Schematic of imatinib mesylate 
 
Table 2-2. Physical properties of α and 𝛽 form imatinib mesylate 
Imatinib mesylate α-form 𝛽-form 
Crystal shape needle-shaped block-shaped 
Hydroscopicity hygroscopic less hygroscopic 
Stability metastable more stable at T<140° C 
flow properties unfavorable more favorable 
Grillo et al. revealed the crystal structure of α-form and 𝛽-form imatinib mesylate and 
found these two polymorphs have significantly different molecular conformations. By 
grinding them, the amorphous imatinib mesylate was produced that converted to a 
crystalline phase by either thermal treatment or aging (Grillo et al., 2012). Veverka et al. 
modified the morphology of α-form imatinib mesylate with various organic solvent 
mixtures by precipitation (Veverka et al., 2012). Srivastava et al. presented a 
comprehensive study of the vibrational spectroscopies of 𝛽-form with the FT-Raman and 
FT-IR spectra (Srivastava et al., 2013). The polymorphic composition of two polymorphs 
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mixture was determined quantitatively with PXRD, ATR-FTIR, and DSC in the literature 
(Bellur Atici and Karlığa, 2015). The results show that PXRD technique is more accurate 
than ATR-FTIR and DSC.  
Despite the mentioned studies, the investigation of the imatinib mesylate properties, 
particularly those related to the crystallization process, was still lacking. The solubility data 
has not been published up to date. In this study, we measured the solubility of two forms 
of imatinib mesylate in three solvents (methanol, 1-propanol, and 2-propanol) from 278.15 
to 333.15 K at atmospheric pressure to study their relative stability. Subsequently, the 
solution-mediated polymorphic transformation (SMPT) from metastable 𝛼-form to stable 
𝛽-form was studied in-situ with Raman spectroscopy and conductivity meter. Finally, the 
nucleation and grow rate of 𝛽-form imatinib mesylate were estimated by minimizing the 
difference between the calculated and experimental solute concentration with MATLAB 
optimization function. 
2.2 Material and experiments 
2.2.1 Material 
The 𝛼-form imatinib mesylate was supplied by Apotex Pharmachem Inc. (Brantford, ON, 
Canada) and used without any further processing. The 𝛽-form was obtained by the 
solution-mediated polymorphic transformation from α-form in methanol. The solvents 
(methanol, ethanol, isopropanol, n-propanol, 1-butanol, acetone, acetonitrile, and 
tetrahydrofuran) with HPLC grade were purchased from Sigma-Aldrich (Milwaukee, WI,) 
and no further purification was performed. 
2.2.2 Characterization 
2.2.2.1 Powder X-Ray Diffraction (PXRD) 
The polymorphs of solid-state 𝛼-form and 𝛽-form imatinib mesylate were identified with 
powder X-ray diffraction (Rigaku, Miniflex, Tokyo, Japan) with the Cu-Kα source ((λ for 
Kα = 1.54059 Å) at room temperature. The conditions of voltage (30kV), current (15mA), 
scan angle (2° to 50°) and scan speed (2°/min) were kept the same for all samples.  
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2.2.2.2 Differential Scanning Calorimetry (DSC) 
Thermal properties of crystals, such as melting point and enthalpy, were measured by 
differential scanning colorimeter ((DSC, Mettler Toledo, Chicago, United States). The 
samples (5-10 mg) were placed in a 40-μl aluminum crucible with a pierced lid for gas 
escaping and then heated from 25°C to 250°C with 10°C/min heating rate under nitrogen 
purge at a flow rate of 40 ml/min.  
2.2.2.3 Optical microscopy and Scanning Electron Microscopy (SEM)  
The optical microscopy (Axioskop 40, Carl Zeiss Light Microscopy, Germany) with a 
magnification of 500 times was used as an off-line method to give a rough judgement of 
the polymorphic composition of solid-state imatinib mesylate in suspension. Scanning 
electron microscope (LEO 1450XB，Zeiss, Oberkochen, Germany) was employed for 
detailed morphologic information. The samples have been coated with coated with 5 nm 
of osmium metal in Osmium Plasma Coater (OPC80T, Filgen Inc. Japan) before SEM 
testing. 
2.2.2.4 Raman spectroscopy 
A Raman RXN Analyzer spectroscopy (Kaiser Optical Systems, Inc., Ann Arbor, MI, USA) 
equipped with a diode laser (784.8-nm) and a fiber optic probe was applied to monitor the 
polymorphic composition of solid-phase during the SMPT process from 𝛼-form to 𝛽-form. 
The characteristic peaks of 𝛼-form and 𝛽-form of imatinib mesylate are at 1664 cm-1 and 
1656 cm-1, and the single point baseline is at 1640 cm-1. 
2.2.3 Solubility measurement  
To study the stability of two forms, we used Ultraviolet-visible spectroscopy (UV-Vis, 
Cary Bio 100 spectrophotometer, Varian, Mississauga, ON) to measure the solubility of 
imatinib mesylate in methanol, 1-propanol, and 2-propanol. The calibration curve of 
“Absorbance-Concentration” should be determined with a series of known concentration 
solutions at room temperature at first. The characteristic UV-Vis absorption band at 271-
nm and 275-nm was applied for quantification in methanol and propanol, respectively. 
Then, an excessive sample was added to the selected solvent in a 5-ml glass vial. The vials 
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were immersed in a constant temperature bath with an accuracy of 0.1 °C and agitated for 
several hours at a specific temperature to reach equilibrium. After 30 mins standing, the 
supernatant was taken by a syringe and filtered with a 0.45-μm membrane syringe filter 
(VWR, Mississauga, ON), followed by proper dilution and concentration measurement 
with UV-Vis. The excess solids in the vials were filtered, dried, and checked with PXRD.  
As the 𝛼-form imatinib mesylate transformed to 𝛽-form in methanol during the solubility 
measurement，the solubility of 𝛼-form imatinib mesylate was determined during the 
transition process (see Section 2.2.4 for more details).  
 
Figure 2-2. UV-Vis absorption spectra of imatinib mesylate in methanol with a 
characteristic peak at 271-nm 
2.2.4 SMPT experiments 
Eight solvents (methanol, ethanol, isopropanol, n-propanol, 1-butanol, acetone, acetonitrile, 
and tetrahydrofuran) were screened for mediating the polymorphism transformation. An 
excessive amount of 𝛼-form imatinib mesylate was added to the solvents and agitated in a 
thermostatic shaker for 2 weeks. The start time of transition was determined by the 
morphology of the crystals remaining in the solution with the microscope. After filtration 
and drying, the crystal polymorph was determined by PXRD.  
Subsequently, the SMPT process from α-form to 𝛽-form imatinib mesylate was 
investigated in methanol at different temperatures. A carefully excess weighed amount of 
α-form was added to 35-ml methanol in a 50-mL double-jacketed crystallizer. The 
crystallizer temperature was kept constant by a water bath circulator (FP-50, Julabo 
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LABORTECHNIK GMBH, Germany). The solute concentration and solid-phase 
polymorphic composition were monitored by a conductivity meter (Pinnacle Series: 
M541P) and Raman spectroscopy. The start and end time of the transition process was 
determined through the morphology of the undissolved crystals with the optical microscope. 
The solubility of 𝛼-form was detected during the SMPT process when the transition did 
not happen. 
2.3 Theory 
2.3.1 Solubility models 
In this work, the solubility of two forms of imatinib mesylate in the selected solvents was 
fitted with the modified Apelblat equation, as shown in Eq. (1-4) 
 𝑙𝑛𝑥 = 𝐴 +
𝐵
𝑇
+ 𝐶𝑙𝑛𝑇 (2-1) 
where 𝑥 is the molar fraction of solute in the solution, 𝑇 is the absolute temperature in 
Kelvin, and 𝐴, 𝐵, and 𝐶 are dimensionless parameters. The value of three parameters were 
estimated with MATLAB curve fitting toolbox. 
The solubility, in molar fraction, can be calculated using Eq.(2-2): 
 𝑥 =
𝑚/𝑀
𝑚/𝑀 + 𝑚𝑠/𝑀𝑆
 (2-2) 
where 𝑚 and 𝑚𝑠 are the mass of solute and solvent, 𝑀 and 𝑀𝑆 are the molecular mass of 
solute and solvent, respectively. 
Solubility reflects the Gibbs energy and stability. The more stable a polymorph is, the 
lower the solubility it is at a given temperature. The difference of Gibbs free energy 
between two polymorphs relates to the solubility by Eq. (2-3) 
 ∆𝐺 = 𝑅𝑇𝑙𝑛 (
𝑎1
𝑎2
) ≈ 𝑅𝑇𝑙𝑛 (
𝑥1
𝑥2
) (2-3) 
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where ∆𝐺 is the difference of Gibbs free energy (J/mol), and 𝑎 is the solute activity in the 
solution(Grunenberg et al., 1996).  
2.3.2 Transition process 
The SMPT process consists of three steps: the dissolution of metastable form, nucleation 
of stable form and growth of stable form. The empirical equations for secondary nucleation 
and growth rate are expressed as Eq. (2-4) and (2-5) (Ranodolph, 2012):  
 𝐵𝑠𝑛 =
𝑑𝑛0
𝑑𝑡
= 𝑘𝑠𝑛𝑀𝑇
𝑗𝑆𝑏 (2-4) 
 𝐺 =
𝑑𝐿
𝑑𝑡
= 𝑘𝑔𝑆
𝑔 (2-5) 
where 𝐵𝑠𝑛  is secondary nucleation rate [#/(m
3∙ 𝑠)], 𝐺  is growth rate (m/s), 𝑆 is relative 
supersaturation, 𝑀𝑇 is suspension density (kg solute /kg solvent). 𝑘𝑠𝑛 , 𝑘𝑔, 𝑗, 𝑏 and 𝑔 are 
parameters, representing the nucleation rate coefficient, growth rate coefficient, nucleation 
order on suspension density, nucleation order on supersaturation, and growth order on 
supersaturation. 
 𝑆 =
𝐶 − 𝐶∗
𝐶∗
 (2-6) 
where 𝐶 is the solution concentration, and 𝐶∗is the equilibrium concentration both in kg 
solute /kg solvent. 
2.3.3 Parameter estimation 
The population balance equation (PBE) coupled with solute mass balance provides a 
mathematical framework of the crystallization processes. The PBE with the Lagrangian 
approach (Ranodolph, 2012) describes the change in crystal population density with 
respect to time and space, as shown in Eq. (2-7). 
 
𝜕𝑛
𝜕𝑡
+ 𝛻. (𝑣𝑒𝑛) + 𝛻. (𝑣𝑖𝑛) = 𝐵 − 𝐷 (2-7) 
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where 𝑛 is population density, 𝑣𝑒 is external velocity vector, 𝑣𝑖 is internal velocity vector, 
B is crystal birth rate, and D is crystal death rate. Assuming that a crystallizer has a uniform 
distribution of suspended solids, a size-independent growth rate, and negligible breakage 
and agglomeration, Eq. (2-7) can be simplified to a 1-D PBE as following when 𝐿 ≠ 0: 
 
𝜕𝑛(𝑡, 𝐿)
𝜕𝑡
+ 𝐺(𝑡)
𝜕𝑛(𝑡, 𝐿)
𝜕𝐿
= 0 (2-8) 
The boundary condition at 𝐿 = 0 is  
 𝑛(𝑡, 0) =
𝐵(𝑡)
𝐺(𝑡)
|𝐿=0 (2-9) 
Hu et al.(Hu et al., 2005) proposed a methodology by converting Eq. (2-8) from a partial 
differential equation (PDE) to a set of ordinary differential equations (ODE). The method 
was applied in this study to solve Eq. (2-8) in MATLAB software. The single objective to 
minimize the sum of squares of the difference between the calculated and experimental 
solute concentration of all independent experiments is defined, 
 𝑚𝑖𝑛   𝐹 = ∑ ∑(𝐶𝑖,𝑘
𝑒𝑥𝑝
− 𝐶𝑖,𝑘
𝑐𝑎𝑙)
2
𝑁
𝑖=1
𝑘
𝑘=1
 (2-10) 
where 𝑁  is the sample number and 𝑘  is the experiment number. 𝐶𝑖,𝑘
𝑒𝑥𝑝
and 𝐶𝑖,𝑘
𝑐𝑎𝑙 
experimental and calculated solution concentration, respectively. In this work, the last step 
of SMPT process at different temperature was used to estimate the parameters of nucleation 
and growth rate of 𝛽-form imatinib mesylate. The single objective function was solved 
with the MATLAB optimization function, 𝑓𝑚𝑖𝑛𝑐𝑜𝑛, based on the sequential quadratic 
programming (SQP) method.  
The solute mass balance is  
 
𝑑𝐶(𝑡)
𝑑𝑡
= −3𝑘𝑣𝜌𝑐 ∫ 𝐺(𝑡, 𝐿)
∞
0
𝑛(𝑡, 𝐿)𝐿2𝑑𝐿 (2-11) 
where 𝑘𝑣 is the crystal volume shape factor (𝑘𝑣=1 for a cube), and 𝜌𝑐 is crystal density. 
41 
 
The average relative deviation (ARD) was introduced to evaluate the accuracy of 
estimation, 
 𝐴𝑅𝐷 =
1
𝑁
∑ |
𝐶𝑖,𝑘
𝑐𝑎𝑙 − 𝐶𝑖,𝑘
𝑒𝑥𝑝
𝐶𝑖,𝑘
𝑒𝑥𝑝 |
𝑁
𝑖=1
 (2-12) 
2.4 Results and discussion 
2.4.1 SEM, PXRD and DSC 
α-form imatinib mesylate supplied by Apotex Pharmachem Inc, and 𝛽-form transformed 
from α-form in methanol at 293K were used for SEM, powder XRD, and DSC test. 
Figure 2-3 shows the SEM images of the α-form and 𝛽-form imatinib mesylate. Obviously, 
the 𝛼-form is needle-shaped while 𝛽-form is cubic-shaped. According to the morphology, 
we can distinguish the crystal polymorph easily. 
 
Figure 2-3. SEM images of imatinib mesylate. Left: α-form (3-𝝁𝒎), Right: 𝛽-form 
(10-𝝁𝒎) 
Figure 2-4 displays the powder XRD patterns of 𝛼-form and 𝛽-form imatinib mesylate. 
The results are consistent with the 𝛼-form and 𝛽-form single-crystal XRD patterns, which 
were collected at 293K by Grillo et al.(Grillo et al., 2012) and deposited in the Cambridge 
Crystallographic Data Center with publication numbers CCDC 821869 and 821871. 𝛼-
form shows strong peaks at scattering angle (2𝜃) of 4.8°, 10.4°, 14.8°, 19.0°, 24.8° and 
28.5°, whereas 𝛽-form has characteristic peaks at 9.7°, 13.9°, 18.2°, 20.0° 21.1° and 30.8°. 
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The distinct differences on the XRPD spectrum can be used for polymorph identification 
of imatinib mesylate. 
 
Figure 2-4. The XRD patterns of 𝛼-form and 𝛽-form imatinib mesylate 
For both of 𝛼-form and 𝛽-form imatinib mesylate, there is only one endothermic peak 
observed in the DSC curves (Figure 2-5). The peaks are related to the melting event, which 
was confirmed with hot-stage microscopy and thermogravimetric analysis. The onset (start 
point) of the peak corresponds to the melting point, and the heat of fusion is equal to the 
integral of heat flow over time divided by sample mass. According to the heat of fusion 
rule (Burger and Ramberger, 1979), 𝛼-form and 𝛽-form imatinib mesylate are 
enantiotropic, as the 𝛼-form imatinib mesylate has higher melting point and lower heat of 
fusion than 𝛽-form. 
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Figure 2-5. The DSC curves at a heating rate of 10 K/min of 𝛼-form and 𝛽-form 
imatinib mesylate 
2.4.2 Solubility  
The PXRD results of the residual solids demonstrated that no transformation or conversion 
occurred during the solubility experiments, except for the 𝛼-form in methanol. Figure 2-6 
shows the solubility of 𝛼-form and 𝛽-form imatinib mesylate in methanol, 1-proponal and 
2-proponal. As shown in Figure 2-6, the 𝛼-form has higher solubility than 𝛽-form in 
methanol,1-proponal and 2-proponal. The solubility order for both forms is methanol>1-
propanol >2-propanol. The fitting parameters are listed in Table 2-3 and the results indicate 
that the modified Apelblat equation matches the solubility well with all R2 greater than 
0.99. 
  
Figure 2-6. The molar fraction solubility of 𝛼-form and 𝛽-form imatinib mesylate in 
methanol, 1-proponal and 2-proponal. Dashed line: calculated curve with modified 
Apelblat equation 
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Table 2-3. Parameters of the modified Apelblat equation for imatinib mesylate in 
three solvents 
 
  A B C R2 
Methanol 
𝛼-form -685.8 2.73E+04 103.5 1 
𝛽-form 144.2 -8.61E+03 -21.24 0.9938 
1-proponal 
𝛼-form -279.2 9116 42.11 0.9983 
𝛽-form -762.2 3.18E+04 113.4 0.9972 
2-proponal 
𝛼-form -455.2 1.66E+04 68.38 0.9982 
𝛽-form -933.4 3.89E+04 139 0.9949 
As concluded above, 𝛼-form and 𝛽-form imatinib mesylate are enantiotropic. Figure 2-7 
presents that the difference of Gibbs free energy between 𝛼-form and 𝛽-form imatinib 
mesylate increases with temperature. So, the transition temperature should be lower than 
283.15K, which means that the 𝛽-form is always more stable than 𝛼-form above 283.15K. 
 
Figure 2-7. The difference of Gibbs free energy between 𝛼-form and 𝛽-form 
imatinib mesylate in methanol, 1-proponal and 2-proponal 
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2.4.3 Solution-Mediated Polymorphic Transformation (SMPT)   
Through the solvent screening, we found that the SMPT from α-form to 𝛽-form imatinib 
mesylate could occur in methanol, ethanol, isopropanol, n-propanol, and 1-butanol. The 
transition time increased with the solvent in the order of methanol, ethanol, 1-propanol, 2-
propanol and 1-butanol. Thus, methanol was chosen as the solvent to investigate the SMPT 
process at different temperatures by in-situ Raman spectroscopy and conductivity meter. 
Due to the apparent fluctuations in the baseline, the relative heights of the Raman spectrum 
were used for quantitative analysis to reduce the effect produced by disturbance variables 
(Caillet et al., 2006). Here, the peaks at 1664 cm-1 and 1656 cm-1 were selected as the 
characteristic peaks of 𝛼-form and 𝛽-form imatinib mesylate, and the single point baseline 
was at 1640 cm-1. Generally, the conductivity of a binary conducting solution is a function 
of temperature and solute concentration. For an isothermal process, conductivity increase 
in direct proportion to concentration, so the conductivity meter can be used for real-time 
measurement of the concentration. 
 
Figure 2-8. Raman spectra of 𝛼-form and 𝛽-form imatinib mesylate 
Figure 2-9 displays how the concentration and solid composition change during the SMPT 
process in methanol at 293.15K. The process can be divided into four steps. At the 
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beginning, the concentration increased rapidly as 𝛼-form dissolved, and the undissolved 
solid was pure 𝛼-form. The second step involves the nucleation of 𝛽-form. Meanwhile, the 
conductivity and the Raman intensity for both forms kept constant. The dissolution of 𝛼-
form and growth of 𝛽-form happened during the third step, resulting in a decreased Raman 
intensity of 𝛼-form and an increased intensity of 𝛽-form. In the last step, the Raman 
intensity of 𝛼-form did not change, illustrating that all 𝛼-form crystals had been dissolved 
and the solid-phase were pure 𝛽-form. The nucleation and growth of 𝛽-form led to the drop 
of conductivity and a gradual increase of Raman intensity of 𝛽-form. 
During the SMPT process, namely the third step, the concentration was close to the 
solubility of 𝛼-form, which indicated the dissolution rate of 𝛼-form is much faster than 
growth rate of 𝛽-form. Therefore, it can be concluded that the SMPT from 𝛼-form to 𝛽-
form imatinib mesylate is nucleation-growth controlled of 𝛽-form. 
 
Figure 2-9. Solution-mediated polymorphic transformation from α-form to 𝛽-form 
imatinib mesylate at 293k 
2.4.4 Kinetic parameter estimation  
As mentioned in Section 2.4.3, all 𝛼-form crystals had dissolved and only 𝛽-form crystals 
existed in the solid-phase in the last step (step 4) of the solution mediated polymorphic 
transformation. Therefore, the last step of the SMPT process can be regarded as a seeded 
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isothermal batch crystallization. During the process, the solute concentration was measured 
by the conductivity meter and the suspension density was calculated by solute mass balance. 
Hence, the nucleation and growth can be estimated through minimizing the difference 
between the calculated and experimental solute concentration measured in all independent 
experiments. The estimated parameters are listed in Table 2-4. 
The nucleation order with respect to supersaturation (𝑏) is much higher than the nucleation 
order with respect to suspension density (𝑗), indicating that supersaturation affects the 
secondary nucleation rate more significantly than slurry density does. In addition, 𝑏 > 𝑔 
shows that the nucleation rate has a stronger relationship with supersaturation than the 
growth rate, hence the mean crystal size will decrease at high supersaturation. The 
estimated kinetic parameters are useful for optimizing and controlling the cooling 
crystallization process of 𝛽-form imatinib mesylate. 
Table 2-4. Kinetic parameter estimated from optimization 
Kinetic parameter Estimated value Units  
𝑘𝑏  9.22 ×10
11 [(#/𝑚3 ∙ 𝑠)/(𝑘𝑔/𝑘𝑔𝑠𝑜𝑙𝑣𝑒𝑛𝑡)𝑗] 
𝑗 0.754 [−] 
𝑏 3.12 [−] 
𝑘𝑔 9.12 ×10
-11 [𝑚/𝑠] 
𝑔 1.23 [−] 
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Figure 2-10. Calculated and experimental solution concentration 
a)284.75 K, b)293.65 K, c)302.95 K and d) 313.15K 
The calculated and experimental solute concentration at different temperatures are plotted 
in Figure 2-10. The ARD of the four experiments are 7.6%, 12.19%, 6.44 %, and 8.62%, 
respectively, which indicates the empirical equations (Eq. 4, 5, 7) used in this work are 
suitable for 𝛽-form imatinib mesylate. The PBE combined with agglomeration and 
breakage would give better estimation performance with considerable increase in 
computation time. 
2.5 Conclusions 
In this work, the α-form and 𝛽-form imatinib mesylate, were characterized by powder X-
ray diffraction, scanning electron microscopy and differential scanning calorimetry firstly. 
Then, we measured their solubility in methanol,1-propanol, and 2-propanol with UV-Vis. 
The modified Apelblat equation was used to fit the solubility data. According to the DSC 
and solubility results, we found that α-form and 𝛽-form imatinib mesylate are 
enantiotropically related and the transition temperature is lower than 283.15K. Above 
283.15K, 𝛼-form always has a higher solubility and lower stability than 𝛽-form in methanol, 
1-proponal and 2-proponal. The solubility order in selected solvents is methanol>1-
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propanol>2-propanol. After solvent screening, the solution-mediated polymorphic 
transformation (SMPT) from α-form to 𝛽-form imatinib mesylate was investigated in 
methanol. The solute concentration was monitored by a conductivity meter, while the solid 
phase was monitored by Raman spectroscopy. As the concentration was close to the 
solubility of metastable form during the SMPT process, it can be concluded that SMPT 
process of imatinib mesylate from 𝛼-form to 𝛽-form in methanol is controlled by 
nucleation and growth of 𝛽-form. Finally, the nucleation and grow rate of 𝛽-form of 
imatinib mesylate were estimated by minimizing the difference between the calculated and 
experimental solution concentration with MATLAB optimization function.  
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3 Simultaneous Measurement of Solution Concentration and 
Slurry Density by Raman Spectroscopy with Artificial 
Neural Network 
Abstract 
In this work, the capability of Raman spectroscopy to measure the solution concentration 
and slurry density simultaneously and quantitatively was studied. Paracetamol-ethanol and 
L-glutamic acid-water systems were chosen as model systems. Different pre-processing 
methods (spectra range selection, baseline removal, direct orthogonal signal correction-
DOSC or no processing) and multivariable analysis techniques (characteristic peaks 
regression (CPR), principal component regression (PCR), partial least squares regression 
(PLSR) and artificial neural network (ANN)) were applied and compared based on the root 
mean squared error (RMSE). It was demonstrated that the solution and solids concentration 
can be extracted separately from Raman spectroscopy. It is found that DOSC pre-
processing can improve the fitting performance of the linear regression models (CPR, PCR, 
and PLSR), but not for ANN model. On the other hand, ANN method, owing to its non-
linear prediction ability, had better predicted results than the linear models when the signal 
was weak. 
3.1 Introduction  
Crystallization is one of the oldest unit operations and widely used for separation and 
purification in chemical industry. The driving force for crystallization process is 
supersaturation, which is the difference/ratio between the actual temporal concentration 
and the solubility. The desupersaturation profile has a significant effect on the product 
quality. Therefore, the concentration measurement is essential for design and optimization 
of the crystallization process. 
Several techniques have been employed to determine the solution concentration, such as 
gravimetric method (Zhang et al., 2010), high-performance liquid chromatography (HPLC) 
(Li et al., 2016), ultraviolet/visible spectrophotometer (Mondal et al., 2017), conductivity 
meter (Cheng et al., 2006), attenuated total reflectance Fourier transform infrared (ATR- 
FTIR) spectroscopy (Yang et al., 2008) and Raman spectroscopy (Hu et al., 2005). With 
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the gravimetric method, HPLC, or off-line UV/vis, the samples have to be removed from 
the crystallizer, followed by drying, filtration, and/or dilution steps, which is time-
consuming and induce inaccuracy in the measurement. On the contrary, the in-situ process 
analytical technologies (PAT) are more convenient and accurate to monitor crystallization 
process and implement feedback control. 
ATR-FTIR is the most common PAT tool for solution concentration measurement. Due to 
the low penetration depth (about 2-3μm) of ATR-FTIR beam, the ATR-FTIR probe can 
monitor liquid-phase in spite of the existence of the solid-phase (Nicoud et al., 2019) 
(Cornel et al., 2008). However, it is difficult to characterize the systems that have low 
solubility or low infrared activity with ATR-FTIR (Bötschi et al., 2018). 
Raman spectroscopy is another in-situ PAT tool that has been used widely for monitoring 
the polymorphic composition of the solid phase (Nicoud et al., 2019). The solid 
concentration for each polymorph is usually calculated by mass balance, assuming the total 
solute mass in the crystallizer is constant during the crystallization process. Nevertheless, 
this assumption only holds for the batch crystallization process or the continuous 
crystallization in steady-state condition. In case of unsteady continuous crystallization, the 
solute may accumulate/dissipate during the process, defying the assumption.  
On the other hand, few studies have been performed in the literature to utilize Raman for 
the solution concentration measurement. For the first time, Hu et al.(Hu et al., 2005) 
demonstrated that Raman can measure the solute concentration in liquid-phase and 
polymorphic form in solid-phase simultaneously in flufenamic acid systems. Later, Cornel 
et al. successfully estimated the solution concentration and slurry density of L-glutamic 
acid, in spite of the complete overlap in the signals of liquid phase and solid phase (Cornel 
et al., 2008). Raman spectroscopy method to measure the solute concentration of 
paracetamol and carbamazepine were developed by Powell et al.(Powell et al., 2016) and 
Acevedo et al (Acevedo et al., 2018). 
It is worth noting that all the aforementioned references employed the multiple linear 
regression (MLR) models to relate the measured variables (e.g. Raman or FTIR 
spectroscopies) to the independent variables (e.g. solution concentration or polymorphic 
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composition). Three MLR models were widely applied. The first one, characteristic peak 
regression (CPR), relies on the absolute height/area of the characteristic peaks or the 
difference/ratio of the intensities of two characteristic peaks (Nicoud et al., 2019). 
Compared to the other two models, namely, principal component regression (PCR)(Cornel 
et al., 2008) and partial least squares regression (PLSR) (Powell et al., 2016), the 
characteristic peak method is more straightforward, but it is time-consuming to select the 
peaks manually and subject to human error. Since PCR and PLSR utilize the full spectrum 
instead of some specific peaks, their results are more accurate than peak selection method 
(Cornel et al., 2008)(Pratiwi et al., 2002). In addition, PCR and PLSR can overcome 
the multicollinearity problem that is common in spectroscopy.  
Artificial neural networks (ANN), which is a non-linear modeling technique, has 
successfully predicted the polymorphic composition in multi-component powder mixtures 
from diffuse reflectance FTIR spectroscopy (Kachrimanis et al., 2007) and the co-crystal 
formulations from Raman and ATR-FTIR spectroscopy (Barmpalexis et al., 2018). It was 
demonstrated that the ANN model has better fitting performance than PLS regression in 
these two cases (Kachrimanis et al., 2007). 
The objective of this paper is to develop a simple analytical method to quantitatively 
measure the solution concentration and slurry density from Raman spectrum directly, with 
the aid of the MLR models (CPR, PCR, and PLSR) and non-linear ANN models, without 
imposing any assumption. In this work, paracetamol-ethanol and L-glutamic acid-water 
were chosen as model systems. Two polymorphs of L-glutamic acid and one stable form 
of paracetamol were investigated. This article is organized as follows. First, the 
experiments for collecting training data for establishing the models are described. Different 
preprocessing and multivariable analysis were applied to estimate the solution and solids 
concentration from Raman spectra, and their performance were compared based on the 
mean squared error (RMSE). Then, the validation experiments were designed to verify the 
reliability of the developed models. Finally, the conclusions of this work are presented. 
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3.2 Experimental section 
3.2.1 Material 
Paracetamol (stable form I PCM, 98%, Sigma-Aldrich Chemical Inc., MO, USA), ethanol 
(100%, Commercial Alcohols Inc., ON, Canada), L-Glutamic acid (stable 𝛽-form LGA, 
99+ %, Alfa Aesar, MA, USA), and deionized water supplied in our lab were used in this 
study without any further processing. The metastable α-form LGA was produced by fast 
cooling crystallization from aqueous solution, followed by filtration and drying. All 
polymorphs were identified with powder X-ray diffraction (PXRD, Rigaku, Miniflex, 
Tokyo, Japan). The comparison between the theoretical and experimental PXRD patterns 
of PCM and LGA is shown in Figure 3-1and Figure 3-2, respectively. The theoretical 
patterns were generated from the files downloaded from Cambridge Crystallographic Data 
Center (CCDC deposition number: Form I PCM-735853, 𝛼-form LGA- 1206530, 𝛽-form 
LGA- 1206531) with software Mercury (version 3.10.3, CCDC, Cambridge, UK). α-form 
LGA shows strong scattering at the angle of 18.3°, 23.7°, 26.7°, and 37.0°, whereas the 
characteristic peaks of 𝛽-form LGA are at 10.3°, 13.7°, 20.0°, 20.5°, 25.6°, 26.1° and 35.6°. 
 
Figure 3-1. PXRD patterns of Form I paracetamol 
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Figure 3-2. PXRD patterns of 𝛂-form and 𝛃-form L-glutamic acid 
3.2.2 Raman spectroscopy 
The Raman spectrum was collected by a Raman RXN Analyzer spectroscopy (Kaiser 
Optical Systems, Inc., Ann Arbor, MI, USA) coupled with a diode laser (784.8-nm) and a 
fiber optic probe. The data was acquired by the iCRaman software (Mettler Toledo, 
Columbus, OH) in the Raman shift range of 3425-100 cm-1 with a resolution of 1 cm−1. 
Due to the weakness of the solution concentration signal and the readout noise of the charge 
coupled device (CCD) detector, one accumulation with 15s exposure time was used to 
increase the signal/noise ratio. 
The ambient fluorescent light may attribute to some prominent peaks in the Raman 
spectroscopy. These peaks vary with the slurry concentration due to the obstruction of the 
ambient light. Therefore, the experiment should be carried out with a shaded container to 
prevent the undesired spikes in the results. In this study, all the experiments were done in 
the crystallizers, whose surface are covered by black tape, to eliminate the effect of the 
ambient light. It was demonstrated by experiments that the Raman spectrums kept same 
regardless of the presence and absence of outer lights.  
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3.2.3 Training data collection 
The training datasets were obtained with some prepared solutions/suspensions, whose 
solution concertation and slurry density of each polymorph were known. The inputs of the 
model were temperature and Raman spectrum, and solution concentration and slurry 
density were considered as the output of the model. The temperature was measured by a 
digital temperature sensor DS1820 (Maxim Integrated, Inc., CA, USA). Figure 3-3.a shows 
the schematic design of the experimental setup used in this study. The Simulink program 
built for merging the input and output data simultaneously is shown in Figure 3-3.b. 
 
Figure 3-3. a) Schematic of the experimental setup (Note: the surface of crystallizer 
was covered by black tap); b) Simulink block diagram for data acquisition 
The dataset included three parts: pure solvent at different temperature, clear solution with 
different concentrations at different temperature, and suspension with different slurry 
density at different temperature. At first, the Raman spectrum of pure solvents at different 
temperature was measured. Secondly, the dataset of clear solution with different 
concentrations at different temperature was collected. The procedure is illustrated in Figure 
3-4.a. A solution with known low concentration was prepared at room temperature and 
then heated to a high temperature to ensure all crystals were dissolved. Next, the system 
was cooled to enter the metastable zone. The solution temperature and Raman spectrum 
were recorded during the cooling process. Focused beam reflectance measurement (FBRM) 
(S400, Mettler Toledo, WA, USA) was used to confirm no nucleation happened. After that, 
a known amount of crystals was added to the solution to increase the solution concentration. 
By repeating the heating, cooling, and crystal addition steps, the Raman spectrum of clear 
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solutions for a range of concentrations and temperatures, both in the unsaturated zone and 
metastable zone, were collected. The solution concentration was calculated by the mass of 
the added crystals. Lastly, the dataset of suspension with different slurry density was 
obtained by adding various amount of crystals to the saturated solutions at different 
temperature, as shown in Figure 3-4.b. The solution concentration was assumed to be 
saturated, and the slurry density was calculated through the solute mass balance. 
 
Figure 3-4. Illustration of data collection procedure for 𝛃-form LGA: a) clear 
solution and b) suspension  
3.2.4 Data preprocessing 
To improve the model performance and reduce the effect of irrelevant variables, three 
preprocessing methods were investigated: 1) baseline removal to eliminate the baseline 
shifting problem, 2) spectral range selection to reduce the dimensionality of the input data,  
and 3) direct orthogonal signal correction (DOSC)(Westerhuis et al., 2001) to remove the 
variables in the input data that are orthogonal to the outputs and to reduce the variation that 
is caused by system random fluctuations. The baseline removal of the full spectrum was 
implemented with Matlab function ‘msbackadj’ with default setting (200 for window size 
and step size). The wavenumber range, from 1825 cm-1 to 100 cm-1, were selected as the 
optimal spectral range, since the prominence peaks for both systems are located in this 
spectra region.  
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3.2.5 Multiple Linear Regression (MLR) 
As the temperature and Raman intensities have different orders of magnitudes, the 
standardization algorithm was adopted to normalize the input data by subtracting its mean 
and then dividing each data point by its own standard deviation to avoid numerical 
instability problem. After the standardization procedure, CPR, PCR, and PLSR were 
applied as the MLR models for comparison with the ANN model, and was completed with 
Matlab software. To implement CPR, the ‘findpeaks’ function was used to find the 
intensities of most characteristic peaks, and the ‘fitlm’ function was employed to establish 
the linear correlation between peak intensities and the known variable (solution 
concentration or slurry density). PCR and PLSR, on the other hand, used the principal 
components to reduce the dimension of the input signal, which can be achieved in Matlab 
with ‘pca’ and ‘plsregress’ functions. The numbers of principal components of PCR and 
PLSR were chosen with cross-validation. 
3.2.6 Artificial Neural Networks (ANN) 
ANN was developed with Matlab Neural Network Fitting Tool (‘nftool’).  A two-layer 
Back Propagation Neural Network with four hidden neurons were adopted. The collected 
samples were randomly divided into two sets: 90% for training and 10% for validation. 
The error of the validation set was monitored during the training process to evaluate the 
neural network performance and prevent overfitting by applying “early-stopping” strategy. 
When the training did not improve validation performance for six times, the training was 
stopped to prevent overfitting the neural network. The Levenberg–Marquardt algorithm 
was used for training the ANN, as it is the fastest network training algorithm. Due to the 
high dimensionality of the input data (3327 points), principal component analysis and 
characteristic peak method were used to reduce the dimension of the inputs of the neural 
network and decrease the model complexity. The first 50 components of PCA or the 
characteristic peaks selected by peak method were employed. They are denoted as PCA-
ANN and Peak-ANN, respectively. 
The root mean squared error (RMSE) was used to assess the prediction performance: 
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 𝑅𝑀𝑆𝐸 = √
∑ (?̂?𝑖 − 𝑦𝑖)2
𝑛
𝑖=1
𝑛
 (3-1) 
where 𝑛  is the number of observations, ?̂?𝑖  and 𝑦𝑖  are predicted and observed values, 
respectively. 
3.2.7 Validation experiment 
3.2.7.1 Dilution experiment of PCM-ethanol system 
A dilution experiment was performed to validate the solution concentration models. Pure 
ethanol was continuously pumped into a clear PCM-ethanol solution, and the diluted 
solution was continuously withdrawn. The inlet and outlet flow rates were kept the same 
and constant. The solution concentration during the dilution process can be calculated by 
Eq.(3-2):  
 𝐶 =  𝐶0 × exp (−
𝑡
𝜏
) (3-2) 
where 𝐶0 is initial solution concentration, and 𝜏 is residence time. They are 0.2877 kg/kg 
and 28.5 min, respectively, in this study. 
3.2.7.2 Dissolution and nucleation process of PCM-ethanol system 
An amount of 10.59 g PCM was added to 40 mL ethanol in a 50 mL double-jackets 
crystallizer at 25 ℃ to make a suspension with 0.3355 kg/kg total solute concentration, 
which corresponds to the solubility at 50 ℃. Then the suspension was heated to 60 ℃ with 
a slow heating rate (1 ℃/𝑚𝑖𝑛), followed by cooling the solution back to 25 ℃ at 1 ℃/𝑚𝑖𝑛 
rate.  FBRM was employed to monitor the crystal count.  
The predicted concentrations from Raman were then compared to the solubility equation 
for form I PCM in ethanol, as shown in Eq.(3-3).(Li et al., 2014)   
𝐶𝑓𝑜𝑟𝑚 𝐼 𝑃𝐶𝑀 = 7.915 × 10
−7𝑇3 − 6.439 × 10−4𝑇2 + 1.765 × 10−1𝑇 − 16.17 (3-3) 
where 𝐶 is the solubility in [kg solute/ kg solvent], and 𝑇 is temperature in 𝐾. 
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3.2.7.3 Dissolution process of 𝛃-form LGA-water system 
The solubility[kg solute/kg solvent] of 𝛽-form LGA in water at temperature 𝑇(℃) were 
obtained by fitting the experimental data(Hermanto et al., 2008) with a second-order 
polynomial:  
 𝐶𝛽−𝑓𝑜𝑟𝑚 = 8.664 × 10
−3𝑇2 − 1.925 × 10−1𝑇 + 7.958 (3-4) 
Similar to the heating process of PCM-ethanol system, 0.7803 g of 𝛽-form LGA was added 
to 40 g water at 25℃ to make a suspension with 19.5 g/kg total solute concentration, which 
corresponds to the solubility at 50 ℃. The suspension was heated to 70 ℃ at a slow heating 
rate (1 ℃/𝑚𝑖𝑛) and then cooled back to 25℃.  FBRM was used to monitor the crystal 
count.  
3.3 Results and discussion 
3.3.1 Raman spectroscopy 
 
Figure 3-5. Raman spectra of ethanol, paracetamol and paracetamol-ethanol 
solution 
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Figure 3-6. Raman spectra of powder metastable 𝛂-form and stable 𝛃-form L-
glutamic acid 
Figure 3-5 shows the Raman spectrums of ethanol, PCM crystals, and PCM-ethanol 
solution, while the Raman spectra of solid 𝛼- and 𝛽-form LGA are shown in Figure 3-6. 
The results of solid PCM and LGA agree well with those reported in the literature 
(Kachrimanis et al., 2007). 
The effect of temperature, solution concentrations and slurry density on the Raman spectra 
is shown in Figure 3-7. Compared to the solution concentration and slurry density, the 
temperature has less influence on the spectra. Most peak intensities, such as 866 and 916 
cm-1, changed with both of solution concentration and slurry density, which evidences the 
overlap of the liquid phase and solid phase signals in Raman spectra. Therefore, the 
regression of individual peak intensity vs. slurry density or solution concentration may not 
predict the variable correctly when the other variable is also changing. The deconvolution 
of the spectrum to identify how the peaks are subject to change in the variation of solution 
concentration or slurry density should be taken into full consideration. In this work, the 
mathematical models for solution concentration or slurry density were established 
separately and then applied to measure them from Raman spectrum quantitatively. 
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Figure 3-7. Raman spectra of L-glutamic acid-water system with different a) 
solution concentration of clear solution at 60 °𝑪; b) temperature of clear solution 
with 11.508 g/kg solution concentration; c) 𝜶-form LGA slurry density at 35 °𝑪; d) 
𝜷-form LGA slurry density at 35 °𝑪  
3.3.2 Number of principal components 
The numbers of principal components (PCs) of PCR or latent variables (LVs) of PLSR are 
critical for modeling performance, since a small number of components has low fitting 
capacity, whereas a large number of components may cause overfitting problem. Based on 
the percentage of variance in the response variable (percent variance explained, PVE) and 
mean squared error of prediction (MSEP) by cross-validation (Figure 3-8), the number of 
components was set to 8.  
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Figure 3-8. The percent variance explained (PVE) and mean squared error of 
prediction (MSEP) vs. the number of components of PLSR and PCR for the solution 
concentration of a) paracetamol-ethanol system and b) L-glutamic acid-water 
system 
3.3.3 Results of PCM-ethanol system 
Table 3-1. RMSE (g/kg) results of PCM-ethanol system training data  
System Preprocessing CPR PCR PLS PCA + ANN Peak+ANN 
Solution 
 
None 1.350 2.809 2.149 0.207 0.497 
Baseline removal 1.337 2.497 2.010 0.411 0.406 
Spectral range selection 1.436 2.613 2.040 0.324 0.483 
OSC 0.711 1.002 1.001 1.002 0.706 
Solid 
None 0.406 2.988 2.948 0.886 0.668 
Baseline removal 0.393 2.957 2.755 0.803 0.628 
Spectral range selection 0.609 2.980 2.928 1.033 0.896 
OSC 0.362 0.793 0.793 0.650 0.521 
The RMSE values of the solution and solids concentration of PCM-ethanol system with 
different preprocessing methods and multivariate analysis techniques are summarized in 
Table 3-1. For the PCM solution concentration, the PCA-ANN model with none pre-
processing method results in the lowest prediction error, i.e., 0.2 g/kg. In the case of PCM 
solids concentration, CPR with OSC has better performance than others. The best models 
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were validated with the dilution experiment and used for monitoring the dissolution and 
cooling crystallization processes, as described in Section 3.2.7. 
Figure 3-9 shows a good consistency between the theoretical and predicted solution 
concentration for the dilution experiment. It was observed that the errors increased when 
the solution concentration was lower than 0.15 g/kg, which is the lowest concentration in 
the training dataset, corresponding to the solubility at 10 ℃. This observation suggests that 
the non-linear ANN model may not be capable to reliably extrapolate data out of its training 
range. It is necessary to train the ANN with a full-range dataset to ensure the result validity. 
 
Figure 3-9. Comparison of the theoretical and predicted concentration of PCM-
ethanol solutio 
Figure 3-10 plots the temperature, solution concentration, and FBRM count during the 
heating and cooling processes. Initially, the solution concentration was kept at 0.193 kg/kg 
(solubility at 25 ℃). After system stabilization, the crystallizer was heated so that the 
solution concentration (plotted in black dotted line) increased as a result of the dissolution 
of suspended crystals. At the end of heating process, all of the suspended crystals were 
dissolved. Hence, the solution concentration reached 0.345 kg/kg, which agreed with the 
initial total solute concentration (0.335 kg/kg, the solubility at 50 ℃). After cooling back 
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to 25 ℃, the solution concentration went back to the initial value, as expected. The endpoint 
of dissolution and onset of nucleation detected by Raman (black curve) was also consistent 
with the FBRM readings (red line). This experiment confirms the reproducibility, accuracy, 
and sensitivity of Raman spectrum to the changes in the process. 
 
Figure 3-10. Temperature, solution concentration predicted for Raman, and FBRM 
count during the heating and cooling process of PCM-ethanol system 
3.4 Results of LGA-water system 
Table 3-2 lists the RMSE of regression results of LGA-water system.  It is interesting to 
notice that the RMSE values with ANN model were much lower than those with the linear 
models for three cases of LGA-water system and PCM solution concentration, expect PCM 
solid concentration. The reason for this behavior is that PCM solid concentration has high 
net Raman intensity, so that the characteristic peaks regression couple with DOSC can have 
lowest prediction error. In the cases of PCM solution concentration, LGA solution 
concentration and LGA solid concentration, where the Raman signals were weak relatively, 
ANN model has better prediction performance than the linear models, owing to its non-
linearity of prediction ability. 
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Table 3-2. RMSE (g/kg) results of LGA-water system training data 
System Preprocessing CPR PCA PLS PCA + ANN Peak+ANN 
Solution 
None 1.2526 1.0981 0.7735 0.3465 0.4287 
Baseline removal 1.1264 0.9854 0.6994 0.3145 0.4751 
Spectral range selection 1.3649 1.1435 0.9216 0.3501 0.4548 
OSC 0.6117 0.6357 0.6075 0.5536 0.5547 
Solid 𝛼-
form 
None 1.8708 1.8381 1.3527 0.4421 0.5529 
Baseline removal 1.9121 1.8736 1.3925 0.5086 0.5006 
Spectral range selection 1.9323 1.8697 1.5240 0.4451 0.5175 
OSC 1.0318 1.0306 1.0304 0.5086 0.5626 
Solid 𝛽-
form 
None 2.0605 2.1356 1.6244 0.6549  0.8199 
Baseline removal 2.1622 2.1222 1.6505 0.4830 0.6820 
Spectral range selection 2.2120 2.1413 1.8122 0.5037 0.5226 
OSC 1.2598 1.2613 1.2584 0.4285 0.4650 
 
Figure 3-11. The change of solution concentration and 𝛃-form LGA solid 
concentration during the heating process 
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Figure 3-11 shows the changes of solution concentration and solid concentration of 𝛽-form 
LGA when the crystallizer was heated up with the rate of 1 ℃/𝑚𝑖𝑛. Due to the slow heating 
rate, the solution concentration followed the solubility curve until all solids were dissolved, 
and then kept constant at the solubility corresponding to 50  ℃ . The expected solids 
concentration, presented by the blue solid line, was calculated from the solute mass balance. 
The predicted solution and solids concentrations from Raman spectrum have an excellent 
agreement with the expected results.  
From Table 3-1 and Table 3-2, it can be concluded that DOSC pre-processing methods can 
improve the fitting performance of the linear regression models (CPR, PLSR and PCR), 
but not for ANN model. As mentioned above, DOSC removes the components in the input 
data that are orthogonal to the outputs, which may cause the loss of useful non-linear 
information for ANN model. This observation was also described by Zhu et al.(Zhu et al., 
2008) Among four selected pre-processing methods, none could improve ANN 
performance for all cases. Overall, for strong signals, linear models with DOSC is adequate, 
whereas ANN model is a better choice for weak signals. 
3.5 Conclusion 
Raman spectroscopy is widely used for monitoring the solid phase in crystallization. 
Nonetheless, the study of utilizing Raman spectroscopy to determine the solution 
concentration is rare in the literature. This study demonstrated the ability of Raman 
spectroscopy for determining the solution concentration and solids concentration, 
quantitatively, with paracetamol-ethanol and L-glutamic acid-water systems. Different 
data pre-processing methods and multivariable analysis techniques were applied, and their 
performance were compared. The result showed that DOSC pre-processing improved the 
fitting performance of the linear regression models (CPR, PCR and PLSR), but not for 
ANN model. On the other hand, ANN method, owing to its non-linear prediction ability, 
had better predicted results than the linear models when the signal was weak.  
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4 Identifying the Polymorphic Outcome of Hypothetical 
Polymorphs in Batch and Continuous Crystallizers by 
Numerical Simulation 
Abstract  
Polymorphism is one of the most important challenges in pharmaceutical manufacturing. 
However, the strategy to crystallize the desired polymorph has not been extensively 
investigated, especially in continuous crystallization. In this work, a numerical model, 
incorporating the population balance modeling, was developed considering the nucleation 
and growth rates of metastable and stable forms of a number of pharmaceutical solids. The 
impact of relative nucleation and growth kinetics of the two polymorphs on the 
polymorphic outcome was studied in batch and MSMPR (mixed suspension and mixed 
product removal) crystallizers. In both modes of operation, the simulation results show that 
the growth rate has a more significant effect than the birth rate. In batch crystallizers, an 
indicator has been proposed to analyze the time window to remove the metastable form. In 
MSMPR crystalizer, this indicator can be used to check whether the operating conditions 
(crystallizer temperature, residence time, and inlet concentration) can alter the steady-state 
polymorph. It is found that at high crystallizer temperature, low inlet concentration and 
long residence time, the production of the stable form is favored.  
4.1 Introduction  
Polymorphism refers to the ability of a molecule to crystallize in more than one crystal 
structure with different packing arrangements and/or conformations. It has been reported 
that more than half of the active pharmaceutical ingredients (API) exhibit solid-state 
polymorphism (Stahly, 2007). The polymorphs have different physiochemical properties, 
which have a direct impact on the stability, bioavailability and processability of 
pharmaceutical products (Lee et al., 2011). Crystallization plays an important role in the 
pharmaceutical industry, as over 90% of small molecule drugs exist in crystalline form 
(Variankaval et al., 2008). The crystal properties including purity (Quon et al., 2012), size 
distribution (Vetter et al., 2014), as well as polymorphism, are highly dependent on the 
operating conditions during the crystallization process. 
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Like most chemical processes, the crystallization process can be operated in either batch, 
semi-batch, or continuous mode. In the past several decades, the batch crystallization has 
developed well in the pharmaceutical industry, due to its simpler equipment design and 
higher flexibility of operation. However, the batch-to-batch variability leads to the product 
inconsistency and the substantial issues in the downstream processes, such as filtration, 
drying, and tableting (Chen et al., 2011). Recently, the concept of continuous 
manufacturing has aroused much attention in the pharmaceutical industry, and continuous 
crystallization has been studied by many authors (Alvarez et al., 2011; Eder et al., 2010; 
Lawton et al., 2009). Compared to the batch crystallization, continuous crystallization 
requires smaller equipment sizes and has lower overall costs (Schaber et al., 2011). Also, 
the continuous mode offers higher consistency of products, better control performance and 
more robust scale-up (Ranodolph, 2012), as it operates at steady state over time. Three 
primary types of continuous crystallizers are: mixed suspension mixed product removal 
(MSMPR) crystallizer (Alvarez et al., 2011), tubular crystallizer (Eder et al., 2010), and 
continuous oscillatory baffled crystallizer (Lawton et al., 2009). Among them, MSMPR is 
most convenient, as it can be easily realized by utilizing the existing batch crystallizers.  
In the batch crystallization, the stable polymorph can be obtained easily through the 
solvent-mediated phase transformation (SMPT), but it may be rate-determining and time-
consuming (Beckmann, 2000).  For example, it took six hours for L-glutamic acid in water 
at 45°C (Schöll et al., 2006) and two days for p-aminobenzoic acid in water at 5 °C (Lai et 
al., 2015) for the polymorphic transformation to the stable form. Seeding with the stable 
polymorph can be used to shorten the transition time (Cardew P. T. et al., 1985; Schöll et 
al., 2006). In contrast, seeding with metastable polymorph can help obtain the metastable 
form. Beckmann et al.(Beckmann et al., 1998) used the seeding strategy to produce the 
second metastable form of abecarnil. Also, Doki et al.(Doki et al., 2004) found that 
sufficient seed loadings of the metastable form of glycine crystals resulted in the pure 
metastable form, while low seed loadings led to a mixture of stable and metastable forms, 
whereas the stable form was obtained with no seeding. However, some metastable 
polymorphs cannot be achieved by the seeding method. Nicoud et al.(Nicoud et al., 2019b) 
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observed that seeding of metastable form paracetamol did not lead to the crystallization of 
the metastable form II.  
The study of polymorphism control in continuous crystallization is rare (Wood et al., 2019; 
Zhang et al., 2017). Seeding in the continuous crystallizer has been proven to be 
insufficient for altering the steady-state polymorphism, because the seeds were washed out 
of the crystallizer after several residence times. The metastable form II paracetamol at 0 or 
-10 °C (Nicoud et al., 2019a), metastable 𝛼-form  of p-aminobenzoic at 5 °C (Lai et al., 
2015) and stable 𝛽 -form of L-glutamic acid at 25  °C  (Lai et al., 2014) could not be 
produced continuously from the single-stage MSMPR crystallizer even with the aid of 
seeding with the same polymorph crystals. The simulation result showed that the residence 
time should be greater than 17.4 h in order to obtain the stable form of L-glutamic acid 
(mass fraction>99 wt.%) at 25 °C (Lai et al., 2014). 
From the aforementioned articles, it is noted that obtaining the preferred polymorph of 
different compounds requires different operating strategies in batch and MSMPR 
crystallizers. For paracetamol, the stable form I is the only product in either metastable-
form-seeded batch crystallization or MSMPR. For L-glutamic acid, the stable form is 
hardly obtained from MSMPR crystallizer at 25 °C, but can be accessed at 45 °C in 
MSMPR or by SMPT process within six hours in a batch crystallizer. Whereas, the stable 
form of p-aminobenzoic acid at low temperatures needs two days to complete the SMPT 
process but can be easily and reliably obtained through MSMPR crystallization.  
These mentioned phenomena demonstrate that the nucleation and growth rates of two 
polymorphs, as well as the solvent-mediated polymorphic transformation process, 
contribute significantly to the polymorphic outcome. However, only few studies 
investigate the effects of relative polymorph dynamics on the polymorphic outcome. 
Cardew P. T. et al. (Cardew P. T. et al., 1985) presented a theoretical model for describing 
the SMPT process with the dissolution rate of metastable form and growth rate of stable 
form. Recently, Farmer et al.(Farmer et al., 2016) and Nicoud et al (Nicoud et al., 2019a). 
proposed a mathematical model for polymorph selection in a single MSMPR crystallizer 
with considering the nucleation and growth rates of two forms. Two dimensionless 
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variables, related to manipulated variables (namely residence time, inlet concentration and 
crystallizer temperature) and crystal intrinsic properties (the coefficients and powers in 
nucleation rate and growth rate equations), were defined to identify which form would be 
obtained at steady state. The analytical solution is an effective tool to demonstrate how the 
combination of kinetic parameters and operating condition affect the polymorphism.  
Compared to the analytical method, the numerical method is not only more straightforward 
and applicable for complex kinetic equations, but also can study the parameters 
individually. With the numerical method, Kiho Park et al. (Kiho Park et al., 2016) 
categorized the primary nucleation rate and secondary nucleation rate into three regions: 
primary nucleation dominant region, secondary nucleation dominant region and both 
nucleation comparable region, and studied the optimal cooling strategy of multistage 
MSMPRs for each region in terms of the average particle size and process yield. Later, Li 
and Yang (Li and Yang, 2019) varied the secondary nucleation coefficient and growth 
coefficient to present four cases: faster-nucleation-faster-growth, faster-nucleation-slower-
growth, slower-nucleation-faster-growth, and slower-nucleation-slower-growth; and 
evaluated the effect of wet milling on the particle size and process yield in a single MSMPR 
for each case. Recently, Köllges and Vetter (Köllges and Vetter, 2019) generated the maps 
of polymorphic outcomes at different residence time and feed concentration in a single 
MSMPR coupled with/without the wet milling by using the population balance model. 
However, the effect of the relative kinetics on the polymorphism was not extensively 
investigated.  
The objective of this work is to study the impact of polymorph relative kinetics of a bi-
polymorphic system on the polymorphic outcome, and to investigate the optimal 
crystallization operation to harvest the desired polymorph. The kinetic parameters of the 
hypothetical polymorphs were chosen from the literature and varied in their reasonable 
ranges. The batch and MSMPR crystallizers were numerically simulated with population 
balance and selected kinetic parameters. In our work, the crystal agglomeration and 
breakage are ignored, due to the long computational time (Kiho Park et al., 2016) and the 
lack of agglomeration and breakage parameters for many compounds. The readers who are 
interested in the effect of the breakage on the polymorphism, are referred to the work done 
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by Köllges and Vetter (Köllges and Vetter, 2019). The capability of wet milling for 
polymorph selection in a continuous crystallizer-milling process has been proven 
experimentally and numerically. This work is focusing on the relative kinetics and aiming 
to provide a general approach to determine the crystallization type and operating conditions 
to ensure achieving the desired polymorph in a bi-polymorphic system, when their kinetics 
are known. The methodology presented in this work is also valid for the systems with 
solvates, in which case the mass balance equation should be modified due to the solvent 
loss by crystallization.  
4.2 Process and methodology 
4.2.1 Mathematic Modeling 
The mathematical framework, consisting of population balance and mass balance, was 
developed for batch and MSMPR crystallizers. The high-resolution finite volume method 
(HR-FVM) was used to solve the population balance equations (Gunawan et al., 2004). 
The one-dimensional population balance and solute mass balance in a batch crystallizer 
can be described as (Myerson, 2002): 
 
𝜕𝑛𝑖(𝑡, 𝐿)
𝜕𝑡
+
𝜕[𝐺𝑖(𝑡, 𝐿)𝑛𝑖(𝑡, 𝐿)]
𝜕𝐿
= 0 (4-1) 
 
𝑑𝐶(𝑡)
𝜕𝑡
= −3 ∑ 𝜌𝑐𝑖
𝑖
𝛼𝑉𝑖 ∫ 𝐺𝑖(𝑡, 𝐿)𝐿
2
∞
0
𝑛𝑖(𝑡, 𝐿)𝑑𝐿 (4-2) 
where 𝑖  refers to each polymorph, 𝑛  is the number density in the crystallizer [#/m/kg 
solvent], 𝐿  is the crystal size [m], 𝑡  is time [s], 𝐺  is growth rate [m/s], 𝐶  is the solute 
concentration [kg solute/ kg solvent], 𝜌𝑐
 and 𝛼𝑉  are crystal density [kg/m
3] and shape 
factor.  
For a single MSMPR crystallizer, when the inlet and outlet flow rates are same, the 
population balance and solute mass balance are (Randolph and Larson, 1971): 
80 
 
 
𝜕𝑛𝑖(𝑡, 𝐿)
𝜕𝑡
+
𝜕[𝐺𝑖(𝑡, 𝐿)𝑛𝑖(𝑡, 𝐿)]
𝜕𝐿
−
𝑛𝑖,𝑓𝑒𝑒𝑑(𝑡, 𝐿) − 𝑛𝑖(𝑡, 𝐿)
𝜏
= 0 (4-3) 
 
𝑑𝐶(𝑡)
𝑑𝑡
= −3 ∑ 𝜌𝑐𝑖
𝑖
𝛼𝑉𝑖 ∫ 𝐺𝑖(𝑡, 𝐿)𝐿
2
∞
0
𝑛𝑖(𝑡, 𝐿)𝑑𝐿 +
𝐶𝑓𝑒𝑒𝑑 − 𝐶(𝑡)
𝜏
 (4-4) 
where  𝑛𝑓𝑒𝑒𝑑  is the number density in the feed stream [#/m/kg solvent], 𝜏
 is residence time 
[s], and 𝐶𝑓𝑒𝑒𝑑  is the solution concentration in the feed stream. 
The boundary condition is  
 𝑛𝑖(𝑡, 0) =  
𝐵𝑖(𝑡, 0)
𝐺𝑖(𝑡, 0)
 (4-5) 
where 𝐵 is the nucleation rate [#/s/kg solvent]. The common power law expressions were 
chosen for the nucleation, growth and dissolution rates are given by: 
 𝐵 = (𝑘𝑏1 + 𝑘𝑏2𝑚3)(𝑆 − 1)
𝑏 (4-6) 
 𝐺 = 𝑘𝑔(𝑆 − 1)
𝑔 (4-7) 
 𝐷 = 𝑘𝑑(𝑆 − 1)  (4-8) 
where 𝑘𝑏1  is the primary nucleation rate constant [#/s/kg solvent], 𝑘𝑏2  is the secondary 
nucleation rate constant [#/s/ m3 crystal],  is the third moment of crystals [m3 crystal /kg 
solvent],  and 𝑘𝑑  are growth and dissolution rate constants [m/s], 𝑏 , 𝑔  and 𝑑  are the 
exponents, and 𝑆 is the supersaturation, which is defined as: 
 
𝑆 =  
𝐶(𝑡)
𝐶∗
 
(4-9) 
where 𝐶∗ is the solubility [kg solute/ kg solvent]. The solubility of L-glutamic acids in 
water in the literature (Hermanto et al., 2008) is adopted in this work:   
 𝐶α
∗ = 8.437 × 10−3𝑇2 − 0.03032𝑇 + 4.564 (4-10) 
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 𝐶𝛽
∗ = 7.644 × 10−3𝑇2 − 0.1165𝑇 + 6.622 (4-11) 
4.2.2 Parameter analysis  
The crystal properties and operating conditions are tabulated in Table 4-1. The base values 
and range for the kinetic parameters (listed in Table 4-2) were selected based on the 
literature, especially the work of Brown et al. (Brown et al., 2020), which summarized the 
distributions of crystal kinetic parameters from 185 papers. The base values were used as 
the kinetic parameters of metastable form, while the kinetic parameters of stable form 
varied in the ranges. The ratio between primary nucleation and secondary nucleation rate 
for each polymorph was set to 104. 
The ratio between the nucleation rate constants and growth rate constants of two 
polymorphs are defined as:  
 
𝑅𝑘𝑏 =
𝑘𝑏𝑠𝑡𝑎𝑏𝑙𝑒
𝑘𝑏𝑚𝑒𝑡𝑎𝑠𝑡𝑎𝑏𝑙𝑒
 (4-12) 
 
𝑅𝑘𝑔 =
𝑘𝑔𝑠𝑡𝑎𝑏𝑙𝑒
𝑘𝑔𝑚𝑒𝑡𝑎𝑠𝑡𝑎𝑏𝑙𝑒
 (4-13) 
𝑅𝑑𝑔
 is the ratio of the metastable form dissolution rate to the stable form growth rate, which 
is significant for the polymorphism transition process in batch crystallization. 
 
𝑅𝑑𝑔 =
𝑘𝑑𝑚𝑒𝑡𝑎𝑠𝑡𝑎𝑏𝑙𝑒
𝑘𝑔𝑠𝑡𝑎𝑏𝑙𝑒
 (4-14) 
Table 4-1. Crystal properties and operating conditions in the crystallization process 
Variable Value Range Unit 
Crystal density 1540 - kg/m3 
Shape factor 0.48 - - 
Solvent density 1000 - kg/m3 
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Table 4-2. Base values and variation ranges of the important parameters 
Parameters Base value Range Unit 
𝑘𝑏1  10
8 106 − 1010 [#/s/kg solvent] 
𝑘𝑏2
 1012 1010 − 1014 [#/s/ m3 crystal] 
𝑘𝑔  10
−8 10−10 − 10−6 [m/s] 
𝑏 2 1.5-2.5 - 
𝑔 1 0.5-1.5 - 
𝑘𝑑
 10−5 10−8 − 10−5 [m/s] 
4.3 Results and discussion 
4.3.1 Batch crystallization 
4.3.1.1 Effect of nucleation and growth rate constants 
Batch crystallization operation generally favors the stable form than the metastable form, 
as the stable form always can be obtained with the help of solution-mediated polymorphic 
transformation process. In unseeded batch crystallization, the metastable form always 
crystallizes first, which is known as Oswald’s rule of stages, and then dissolves while the 
stable form grows. The stable form can be readily obtained if the transition rate is fast. 
Conversely, it will take a long time to convert the metastable form to the stable form with 
a slow transition rate. In this case, the metastable form is the preferred product.  
Crystallizer temperature 25 15-35 °𝐶 
Solubility of metastable form 0.0106 0.0069-0.0160 kg solute/kg solvent 
Solubility of stable form 0.008 0.0062-0.0115 kg solute/kg solvent 
Initial concentration 0.0368 - kg solute/kg solvent 
Feed concentration 0.0368 0.02-0.04 kg solute/kg solvent 
Residence time 60 20-120 min 
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Figure 4-1 shows how the solution concentration, solids concentration of the stable form 
and solids concentration of the metastable form change under the unseeded condition with 
different 𝑅𝑘𝑏  and 𝑅𝑘𝑔 . As presented in Figure 4-1(e), the metastable form is suppressed 
by the stable form when two polymorphs have the same rate constants and orders. The 
reason is that the stable form has higher nucleation and growth rates throughout the process 
as the result of higher supersaturation. The results shown in Figure 4-1 also indicate that 
the higher nucleation and growth rates of the stable form can accelerate the polymorphic 
transition process. Furthermore, the transition time in Figure 4-1(c) is much longer than 
Figure 4-1(g), which demonstrates that the ratio between the growth rate constants of two 
polymorphs is more critical than the birth rate ratio in the batch crystallization.   
 
Figure 4-1. Evolution of the solution and solids concentration in the unseeded 
solution-mediated polymorphic transformation at 25 ℃ with different 
𝑹𝒌𝒃 𝐚𝐧𝐝 𝑹𝒌𝒈 when 𝑹𝒅𝒈 = 𝟏𝟎𝟎𝟎. 
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Since the stable polymorph has a lower solubility than the metastable polymorph, the 
system is always more supersaturated with respect to the stable polymorph than the 
metastable polymorph. Hence, the nucleation and growth of stable form cannot be avoided 
when the target product is the metastable form. The metastable form with high polymorphic 
purity can only be achieved when both nucleation and growth rates of stable form are 
relatively slow (Figure 4-1(a)). Furthermore, the metastable product should be removed 
from the solution before the polymorphic transition happens.  
 
Figure 4-2. Simulation of the unseeded batch crystallization with different 𝑹𝒌𝒃 and 
𝑹𝒌𝒈
 at 25 ℃: a) contour plot of the minimum time needed to obtain the 99 wt.% 
stable form; b) contour plot of the time window to remove 99 wt.% metastable form. 
The minimum time needed to complete the polymorphic transition process and crystallize 
the stable form with 99 wt.% purity is plotted in Figure 4-2(a). The criteria are that the 
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mass fraction of the stable form is above 99 wt.% and the solution concentration reaches 
the solubility of the stable form. Figure 4-2(b) shows the time window for removing the 
metastable form from the solution before the transition process happens. The time window 
is counted from the earliest to latest time at which the mass fraction of metastable form is 
higher than 99 wt.% and the solution concentration reaches the solubility of metastable 
form. The results indicate that the higher 𝑅𝑘𝑏  and 𝑅𝑘𝑔
 are, the shorter the time needed for 
obtaining the high purity stable form with high yield and the narrower time window to 
remove the metastable form. It is worth noting that the contours are approximated to 
straight lines with a slope of 1/3 when both axes of 𝑅𝑘𝑏  and 𝑅𝑘𝑔 are in logarithmic scale. 
The reason for the slope equaling to 1/3 is that the secondary nucleation rate is proportional 
to the third moment in this work. Therefore, the equation of the contours can be expressed 
as: 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
= constant. 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
< 0.22 is required to have at least 10 min time 
window to remove the metastable form with 99 wt% purity. 
4.3.1.2 Effect of dissolution rate constant 
The SMPT process is controlled by the slowest step between nucleation and growth of the 
stable form, and dissolution of the metastable form. In Figure 4-1(a-e), the solution 
concentration remains at the solubility of the metastable polymorph during the dissolution 
of the metastable form crystals. Therefore, these cases are controlled by the growth of the 
stable form.  
Figure 4-3 indicates that the SMPT process will be dissolution rate-controlled and take a 
longer time when 𝑅𝑑𝑔  decreases. Usually, the dissolution process is quicker than the 
growth, since the latter involves not only the boundary layer transport resistance but also 
the surface integration resistance (O’Mahony et al., 2012). Hence, in the following 
discussion, the system is assumed as not-dissolution-limited. 𝑅𝑑𝑔 was set to 1000. 
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Figure 4-3. Evolution of the solution and solids concentrations in the unseeded 
solution-mediated polymorphic transformation at 25 ℃ with 𝑹𝒅𝒈 of 1, 10, 100 and 
1000 when 𝑹𝒌𝒃 = 𝑹𝒌𝒈 = 𝟏.
 
4.3.1.3 Effect of nucleation and growth rate orders  
The impacts of nucleation and growth rate orders also have been investigated. The changes 
of the mass fraction of the stable form are presented in Figure 4-4. The lines in the same 
color have the same nucleation rate order 𝑏, while those in the same line styles (dashed, 
solid or dash-dotted) have the same growth rate order 𝑔. The slope change in the curves 
(black dots) corresponds to the starting point of the SMPT process, at which the metastable 
form starts dissolving, leading to the increased slope of the stable form purity. The mass 
fraction of the stable form reaches 1, indicating the completion of the transformation 
process. It is found that increasing 𝑏 and 𝑔 shortens the transition time and the latter has a 
more significant effect. The results also reveal that changing 𝑏 and 𝑔 in their reasonable 
ranges (1.5 to 2.5 and 0.5 to 1.5) does not influence the batch crystallization process as 
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much as 𝑘𝑏  and 𝑘𝑔. This could be explained by the fact that the variation range of kinetic 
constants, is at least an order of magnitude greater than that of the supersaturation term 
(𝑆 − 1)𝑏 or (𝑆 − 1)𝑔. 
 
Figure 4-4. Evolution of the mass fraction of the stable form in the unseeded 
solution-mediated polymorphic transformation at 25 ℃ with different nucleation 
and growth rate orders. 
4.3.2 A single MSMPR 
4.3.2.1 Effect of nucleation and growth rate constants 
 
Figure 4-5. Simulation of the MSMPR crystallization at 25 ℃  with residence 𝝉 = 1 
h and feed concetration 𝑪𝒇𝒆𝒆𝒅 = 𝟎. 𝟎𝟑𝟔𝟖 𝒌𝒈/𝒌𝒈. Contour plot of the mass fraction 
of the stable form at the steady state with a range of 𝑹𝒌𝒃 and 𝑹𝒌𝒈. 
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Unlike the batch crystallization that heads to thermodynamic equilibrium and crystalizes 
the stable polymorph, the continuous crystallization operates at the steady-state and 
produces the crystals based on the relative nucleation and growth rates between two 
polymorphs (Zhang et al., 2017). In this section, the effect of 𝑅𝑘𝑏  and 𝑅𝑘𝑔 on the 
polymorph was investigated in a range of 10−2 to 102. As illustrated in Figure 4-5, the 
contours of stable form mass fraction also can be expressed as 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 = constant. The 
higher constant represents the higher mass fraction of the stable form. The constants for 1, 
5, 50, 95 and 99 wt.% contours were calculated and summarized in Table 4-3, under the 
operating condition listed in Table 4-1. All experimental results of paracetamol, p-
aminobenzoic acid and L-glutamic acid are in agreement with the expected results, as 
shown in Table 4-4. Notably, the 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 of paracetamol is significantly higher than 
the value for 99 wt.% stable form, explaining why the polymorph cannot be altered solely 
by varying the operating conditions (Nicoud et al., 2019a). Hence, changing the solvent or 
adding additives may be an effective method influencing the kinetic ratio of the two 
polymorphs.  
Table 4-3. Constants for the contours of stable form contours 
Stable form wt.% 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 
1 0.0875 
5 0.1488 
50 0.3802 
95 0.7925 
99 1.1574 
Table 4-4. Experimental results and 𝑹𝒌𝒈 ∙ 𝑹𝒌𝒃𝟏/𝟑  of paracetamol, p-aminobenzoic 
acid and L-glutamic acid 
 𝑇 ℃ 𝑅𝑘𝑏 𝑅𝑘𝑔 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
  Polymorph 
paracetamol 0 478 5.019 39.244>>1.1574 stable 
p-aminobenzoic acid 5 1.534 0.935 1.0786>0.7925 stable 
L-glutamic acid 25 0.295 0.115 0.0768<0.0875 metastable 
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From the expression of 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
, one can conclude that 𝑘𝑔  has a more significant effect 
on the product polymorph that 𝑘𝑏  does in MSMPR crystallization. It agrees with the 
findings in the literature (Nicoud et al., 2019a), although different kinetic expressions were 
adopted in our work and the mentioned paper. It indicates that the polymorphic outcome 
in the continuous crystallization is influenced by the growth rate constant, and to a lesser 
extent, by the nucleation rate constant. 
4.3.2.2 Effect of nucleation and growth rate orders 
We also studied the effect of nucleation and growth rate orders on the polymorph in 
MSMPR crystallization. The nucleation and growth rate order of the metastable form were 
fixed at 2 and 1, while the orders of metastable form were changed in the range of 1.5 to 
2.5 and 0.5 to 1.5. The contours of the mass fraction of the stable form at the steady-state 
are plotted in Figure 4-6. It is interesting to note that the mass fraction of the stable form 
drops slightly with the nucleation rate order 𝑏 and growth rate order 𝑔 of the stable form. 
The reason is that the nucleation and growth rate decreases with 𝑏 and 𝑔 when the relative 
supersaturation ( 𝑐/𝑐∗ − 1)  is less than 1. 𝑔  has a greater influence than  𝑏 , which is 
consistent in batch and MSMPR crystallization. 
   
Figure 4-6. Simulation of the MSMPR crystallization at 25 ℃  with residence 𝝉 = 1 
h and feed concetration 𝑪𝒇𝒆𝒆𝒅 = 𝟎. 𝟎𝟑𝟔𝟖 𝒌𝒈/𝒌𝒈. Contour plot of mass fraction of 
the stable form in MSMPR crystallizer at the steady-state with different nucleation 
and growth rate orders 
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4.3.2.3 Effect of operating conditions 
As mentioned in Section 4.3.2, the operating condition has a limited effect on the 
polymorph in some cases, such as paracetamol-water system, due to the faster 
crystallization of the stable form (Nicoud et al., 2019a). Therefore, the attainable region in 
term of polymorph in MSMPR was studied in this section. Crystallizer temperature, 
residence time, and inlet concentration are the main manipulated variables in an MSMPR 
crystallizer. To cover the normal operating range in MSMPR, the residence time was varied 
from 20 to 120 min. The variation ranges of the crystallizer temperature and inlet 
concentration were selected as 15-35 ℃ and 0.02-0.04 kg/kg (equals to the solubility of 
metastable form at 41℃ and 63℃), ensuring that the system is supersaturated with respect 
to both forms. 
Table 4-5. Four cases of the polymorphic systems 
Case Birth rate 𝑅𝑘𝑏  Growth rate 𝑅𝑘𝑔 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
  
a) Stable > metastable 0.1 Stable = metastable 1 0.464 
b) Stable < metastable 10 Stable = metastable 1 2.15 
c) Stable = metastable 1 Stable > metastable 0.1 0.1 
d) Stable = metastable 1 Stable < metastable 10 10 
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Figure 4-7. Mass fraction of the stable form at steady-state obtained from process 
simulation with a range of residence time, inlet concentration and crystallizer 
temperature. Note that the range of color bar is 0 to 1 in (a), 0.9 to 1 in (b), 0 to 0.1 
in (c), and 0.9 to 1and (d). 
The impacts of operating conditions were analyzed in four different cases, as listed in Table 
4-5. The simulation results in Figure 4-7, show different behavior depending on 𝑅𝑘𝑔 ∙
𝑅𝑘𝑏
1/3
. For case b-d, the operating condition has little effect on the polymorph. 
Nevertheless, the mass fraction of stable from in case a) varies from 16.44 % to 99.52 %, 
since its 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is within the range of 5 to 95 wt.% (Table 4-4). As presented in Figure 
4-7(a), the maximum purity of the stable form is achieved with high crystallizer 
temperature, low inlet concentration and long residence time. Increasing crystallizer 
temperature and decreasing inlet concentration benefit the stable form through increasing 
the supersaturation ratio of the two forms and further impacting their relative kinetics, 
while the residence time favors the stable form via providing more time to promote the 
polymorphic transformation. However, these choices are at the expense of process 
productivity. In addition, the result shows that the influences of crystallizer temperature 
and inlet concentration are more significant than residence time, which agrees with the 
previous publication (Lai et al., 2014). 
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In order to quantify the range of 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 in which the manipulated variables can alter 
the polymorphic outcome, the maximum and minimum mass fractions of the stable form 
were plotted versus 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 in Figure 4-8. When 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is between 0.1 and 1, the 
operating conditions, namely crystallizer temperature, residence time, and inlet 
concentration, can effectively control the product polymorph. When 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is around 
0.5, the attainable region is the widest. The mass fraction ranges of the stable form are 
0.002 - 0.108 and 0.734 - 1 when  𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
  is 0.1 and 1, respectively. So the dominant 
product is either the metastable form or the stable form. 
  
Figure 4-8. Attainable region of stable form mass fraction in a single MSMPR  
crystallizer with the operation range listed in Table 4-1.  
4.4 Conclusions 
In this work, the impact of relative kinetics between two polymorphs on polymorphic 
outcome was studied in batch and MSMPR crystallization. In both circumstances, the 
simulation results show that the growth rate has a more significant effect than the birth rate. 
Specifically, growth rate order 𝑔 has a greater influence than the nucleation order 𝑏 on the 
polymorphic outcome, while constant 𝑘𝑔 has a greater influence than 𝑘𝑏 . On the other hand, 
changing 𝑏 and 𝑔 in their reasonable ranges does not influence the polymorphic outcome 
as much as 𝑘𝑏  and 𝑘𝑔 .The parameter 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is an important indicator. In batch 
crystallization, solvent-mediated phase transformation (SMPT) plays an important role in 
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the polymorphic outcome. The stable polymorph always can be obtained through the 
SMPT process. However, the metastable form with high purity can only be achieved before 
the SMPT process happens. 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
< 0.22 is required to have at least 10 min time 
window to remove the metastable form.  In MSMPR crystallization, the polymorphic 
outcome can be altered by the process operation variables (crystallizer temperature, 
residence time, and inlet concentration), when 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is around 0.5. High crystallizer 
temperature, low inlet concentration and long residence favor the production of the stable 
form. The crystallizer temperature and inlet concentration are more significant than 
residence time. When 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is greater than 1 or less than 0.1, the dominant product 
is either the stable form or metastable form, and the operating conditions cannot effectively 
control the product polymorph. In such a case, changing the solvent and adding additives 
are alternative methods to crystallize the desired polymorph by influencing the kinetic ratio 
of two polymorphs. Overall, the stable form with slow kinetics (𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
< 0.1) cannot 
be easily obtained from MSMPR crystallization, but can be accessed by the SMPT process 
in batch crystallization. Collectively, MSMPR crystallization is more dominated by 
kinetics than thermodynamics and is more friendly to metastable form than batch 
crystallization. Based on the above findings, the effort required to design a crystallization 
process for specific polymorph is facilitated once the relative kinetics of two polymorphs 
are known. 
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Effects of Operating Conditions and 
Strategies on the Product Properties of 
L-glutamic acid-water system 
 
 
 
 
 
 
A manuscript will be prepared from the content of this chapter and submitted to a suitable 
scientific journal. 
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5 Effects of Operating Conditions and Strategies on the 
Product Properties of L-glutamic acid-water system 
Crystallization process involves the nucleation, growth/dissolution and 
agglomeration/breakage phenomena, resulting in numerous challenges in controlling the 
product qualities. Furthermore, a number of potential manipulated variables in both batch 
and continuous crystallizers also increase the complexity of the crystallization process. 
Therefore, the experimental method is costly and time-consuming for designing the 
crystallization process properly to produce the desirable product. Alternatively, the 
mathematical modeling can predict the product property in a wide range of operating 
conditions in a short time with minimal experiments, which can help the crystallization 
industries boost the research & development process and reduce the production cost 
(Myerson, 2002). In this chapter, the impact of operating conditions on the product 
properties was investigated thoroughly, including the polymorphism, yield and crystal size 
distribution. 
5.1 Introduction 
As discussed in Section 4.1, batch and MSMPR (mixed suspension and mixed product 
removal) crystallization are the most widely used operation modes for the crystallization 
process. Batch crystallizers are relatively simple and flexible and need a low level of 
maintenance (Myerson, 2002), but suffer from the batch-to-batch variability. In contrast, 
MSMPR operates continuously and can provide high consistency on the product. However, 
there are also several challenges associated with MSMPR crystallization, as discussed 
below: 
1. Crystal size classification and blockage in the transfer tube during the slurry 
withdrawal process. In the laboratory scale, a common method to deal with this 
issue is using an intermittent withdrawal scheme with a peristaltic pump to remove 
the slurry at every 5% (Capellades et al., 2018) or 10% (Lai et al., 2015; Li et al., 
2016; Nicoud et al., 2019; Onyemelukwe et al., 2019) of a residence time with high 
transport velocity. Lührmann et al. (Lührmann et al., 2018) designed a unique 
vessel in which the suspension was removed through the installed lateral and 
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vertical overflow tubes by gravity, instead of pumps, which prevents the 
agglomeration in the pipeline. 
2. Insufficient residence time for crystal nucleation and growth. Based on the 
definition of residence time, one could increase it by using a larger crystallizer or a 
smaller flow rate, but the former would increase the equipment cost and reduce the 
mixing uniformity, while the latter deteriorates the crystal size classification and 
blockage phenomena.  
3. Lower yield than a batch crystallizer. The product yield in MSMPR is defined as: 
 𝑦𝑖𝑒𝑙𝑑 (%) =  
𝐶𝑓𝑒𝑒𝑑 − 𝐶
𝐶𝑓𝑒𝑒𝑑 − 𝐶
∗
× 100 (5-1) 
where 𝐶𝑓𝑒𝑒𝑑 , 𝐶  and 𝐶
∗  are the feed concentration, solute concentration and 
solubility. Unlike batch crystallization always ending at equilibrium-state, the 
continuous crystallization reaches steady-state at which the solution is still 
supersaturated, so the yield of MSMPR crystallization is usually lower than that in 
batch crystallization.  
There are several methods to address the last two issues: a) decreasing the temperature; b) 
increasing the residence time by increasing the crystallizer size or decreasing the flow rate; 
c) increasing the crystal residence time by using multistage MSMPRs, periodic MSMPRs, 
or solids recycle. Su et al. (Su et al., 2017) developed periodic flow crystallization and 
increased the residence time by adding a holding period to MSMPR crystallizer.  Li et al. 
(Li et al., 2016) used solids recycle to increase the solid residence time and thus increase 
the yield close to the theoretical maximum in multistage continuous MSMPR crystallizer. 
Multistage MSMPR crystallizers can overcome the drawbacks of insufficient residence 
time and low yield that exist in a single MSMPR. Compared to a single-stage MSMPR, 
cascaded multistage MSMPRs have longer average residence time and more uniform 
residence time distribution (RTD), so that it can produce larger crystals with a narrower 
CSD. The cascaded multiple-stage MSMPR not only can separate the nucleation and 
growth step of the crystallization process, which is beneficial to produce crystals with 
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desired polymorph and size distribution, but also enhance the process controllability and 
reduce the operation cost (Kiho Park et al., 2016). 
In this chapter, the effects of the operating conditions in batch, single stage and multistage 
MSMPR crystallization configurations on the crystal properties were investigated, 
including the polymorphism, yield and crystal size distribution. L-glutamic acid - water 
was selected as the model system in this chapter, as the L-glutamic acid has been studied 
comprehensively in the literature and the parameters needed for crystallization process 
modeling are available. In this work, the population balance equation was solved by the 
method of characteristics and method of moments. 
5.2 Mathematical model 
L-glutamic acid has two forms: the stable α-form and the metastable 𝛽-form. The 
solubilities of α-form and 𝛽-form are (Hermanto et al., 2008): 
 𝐶α
∗ = 8.437 × 10−3𝑇2 − 0.03032𝑇 + 4.564 (5-2) 
 𝐶𝛽
∗ = 7.644 × 10−3𝑇2 − 0.1165𝑇 + 6.622 (5-3) 
where 𝑇 is the temperature in ℃. The following equations represent the nucleation, growth 
and dissolution equations obtained by Schöll et al (Schöll et al., 2006): 
 𝐵α = 8.0 × 10
5𝑆𝛼
7/3
exp [−
0.1
𝑙𝑛2𝑆𝛼
] (5-4) 
 
 
𝐺α = 0.25 × 10
−7(𝑆𝛼 − 1)
5/6exp [−
0.09
𝑆𝛼 − 1
] (5-5) 
 𝐷α = 3.5 × 10
−5(1 − 𝑆𝛼) (5-6) 
 𝐵𝛽 = 5.4 × 10
4𝑆𝛽
7/3
𝑒𝑥𝑝 [−
15
𝑙𝑛2𝑆𝛽
] + 6.0 × 104𝜇𝛼
2 exp [−
0.001
𝑙𝑛𝑆𝛽
] (5-7) 
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 𝐺𝛽 = 6.5 × 10
−8(𝑆𝛽 − 1)
5/6
exp [−
0.16
𝑆𝛽 − 1
] (5-8) 
𝐵, 𝐺 and 𝐷 are nucleation, growth and dissolution rates. 𝑆𝛼 = 𝐶/𝐶α
∗ and 𝑆𝛽 = 𝐶/𝐶𝛽
∗ are 
the relative supersaturation.  
The seed size distribution is assumed to have a normal distribution and expressed as: 
 𝑛𝑠𝑒𝑒𝑑(𝐿) =
𝐴
√2𝜋𝜎 
exp [−
(𝐿 − ?̅?)2 
2𝜎2
] (5-9) 
where 𝜎 and ?̅? are the standard deviation and average size of the seeds. 𝐴 is an adjustable 
constant to change the seed mass. The seed mass can be calculated from 
 𝑚𝑠𝑒𝑒𝑑 = 𝜌𝑠𝑒𝑒𝑑𝑘𝑉 ∫ 𝑛𝑠𝑒𝑒𝑑𝐿
3
∞
0
𝑑𝐿 (5-10) 
𝜌𝑠𝑒𝑒𝑑  and 𝑘𝑉  are the seed density and its volumetric shape factor. The seed density for both 
forms is 1540 kg/m3. The shape factors for prismatic α-form and needle-shaped 𝛽-form are 
0.48 and 0.031, respectively (Hermanto et al., 2008).  
 
Figure 5-1. Schematics of multiple-stage MSMPR crystallizers 
The population balance and solute mass balance for batch and single MSMPR have been 
described in Section 4.2.1. The schematics of multiple-stage MSMPR crystallizers are 
shown in Figure 5-1. 
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The population balance and solute mass balance for the first MSMPR are the same as the 
single MSMPR, and the subsequent stages have the inlets from previous stage, so their 
balances are   
 
𝜕𝑛𝑖,𝑗(𝑡, 𝐿)
𝜕𝑡
+
𝜕[𝐺𝑗(𝑡, 𝐿)𝑛𝑖,𝑗(𝑡, 𝐿)]
𝜕𝐿
−
𝑛𝑖,𝑗−1(𝑡, 𝐿) − 𝑛𝑖,𝑗(𝑡, 𝐿)
𝜏
= 0 (5-11) 
 𝑑𝐶𝑗(𝑡)
𝑑𝑡
= −3 ∑ 𝜌𝑐𝑖
𝑖
𝑘𝑉 𝑖 ∫ 𝐺𝑖,𝑗(𝑡, 𝐿)𝐿
2
∞
0
𝑛𝑖,𝑗(𝑡, 𝐿)𝑑𝐿 +
𝐶𝑗−1 − 𝐶𝑗(𝑡)
𝜏
 
(5-12) 
where 𝑖 refers to each polymorph and 𝑗 is the MSMPR stage number.  
5.3 Modeling results  
5.3.1 Batch crystallization 
For cooling batch crystallization, the manipulated variables are initial solution 
concentration, temperature profile, and seeding conditions. 
5.3.1.1 Initial solution concentration 
Schöll et al. (Schöll et al., 2006) found that with different initial concentration (43, 48 and 
53g/kg solvent at 45℃) of L-glutamic acid in an unseeded batch crystallization, the 
transformation processes from the metastable form to the stable form have no obvious 
distinction, and the crystal size distributions are very similar for three experiments. The 
modeling results presented in Figure 5-2 show similar behaviors as observed in the 
experiments. 
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Figure 5-2. a) Volumetric crystal size distribution of stable form and b) mass 
fraction of two forms with three different initial concentrations 
However, if the variation range of initial concentration is expanded to 25 to 60 g/kg (Figure 
5-3), the simulation result shows that the transition time increases and the surface-average 
crystal size of the final product decreases monotonically with initial concentration 
increasing. When the initial concentration is within the range of 25-40 g/kg, the 
transformation process and the average size of the final product change significantly with 
the initial concentration. When the initial concentration is higher than 40 g/kg, the 
influences of the initial concentration are negligible. It is concluded that a lower initial 
condition leads to larger crystals at the expense of process productivity. 
 
Figure 5-3. a) Solution concentration profile during the transformation process and 
b) the surface average size of stable form with different initial concentration 
a) b) 
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5.3.1.2 Cooling profile 
The cooling temperature profile of the batch crystallizer can be expressed as  
 𝑇(𝑡) = 𝑇𝑖 − (𝑇𝑖 − 𝑇𝑓) (
𝑡
𝑡𝑐
)
𝑃
 (5-13) 
where 𝑇𝑖 and 𝑇𝑖 are initial temperature and final temperature, 𝑡𝑐 is the total cooling time 
(can be equal to or smaller than the batch time), and 𝑃 is the power number of the cooling 
policy. Three cooling policies, including natural cooling (P=0.1), linear cooling (P=1) and 
near optimal cooling (P=3) were studied for unseeded batch crystallization of L-glutamic 
acid – water system by Sheikholeslamzadeh and Rohani (Sheikholeslamzadeh and Rohani, 
2013). They found that the natural cooling results in a rich content of fine particles and the 
higher value of P leads to a better quality of the product. However, in Sheikholeslamzadeh 
and Rohani’s work, the cooling time was equal to the batch time (two hours), which means 
the system did not reach the equilibrium state at the end of operation. Here, the batch time 
was set to 5 hours and the cooling time was kept at two hours. Figure 5-4 (b) shows the 
high P value favours the production of large crystals of stable form. 
 
Figure 5-4. a) Three different cooling policies and b) the volume average size of 
stable form with different cooling policies  
5.3.1.3 Seeding condition 
Table 5-1. Seed parameters for different cases 
a) b) 
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Cases Mass (g/kg) 
wt% of the stable 
form in seeds 
Average size 
(𝜇𝑚) 
Standard 
deviation (𝜇𝑚) 
Polymorphic 
composition of seeds 
20.3*10% [0:20% 100%] 40 5 
Seed mass 20.3*[0, 5,10, 15,20]% 100% 40 5 
Seed mass 20.3*[0, 5,10, 15,20]% 0% 40 5 
Seed size 20.3*10% 100% 30:20:90 5 
Seed size 20.3*10% 0% 30:20:90 5 
The effect of seed mass, seed size and seed polymorphic composition on the product is 
studied in this section. The feed temperature is 45 ℃ and the initial solution concentration 
is 36.8 g/kg, corresponding to the solubility of metastable form at 60 ℃ . Hence, the 
maximum mass of the crystals is 20.3 g/kg, which is the difference between the initial 
condition and the solubility of the stable form at 45 ℃ (16.5 g/kg).  Seed mass, seed size 
and seed polymorphic composition for different cases are summarized in Table 5-1. 
First, the polymorphic composition of the seeds is investigated. The total seed mass is 10% 
of the maximum mass of the crystals (20.3 g/kg). The average size and standard deviation 
of seeds are 40𝜇𝑚 and 5𝜇𝑚. Figure 5-5(a) shows that the higher the mass fraction of the 
stable form is, the faster the transformation process is, which is due to the less metastable 
forms crystals that need to transform to the stable form. This is also due to the larger surface 
of stable form crystals for secondary nucleation and growth. Figure 5-5(b) shows that the 
average size of the product decreases with the increase in the mass fraction of the stable 
form. The reason may be that the more seeds of the stable form added into the 
crystallization cause the lower average supersaturation that can be consumed by each 
crystal. 
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Figure 5-5. Effect of seeds polymorphic composition on the transformation process 
and crystal size distribution 
Then, the effect of the seed mass of pure stable form and metastable form is studied. The 
seed mass was decided by the percentage of the maximum mass of the crystals. The average 
size and standard deviation of seeds were kept as 40𝜇𝑚 and 5𝜇𝑚. Figure 5-6 (a) shows 
adding the seeds of the stable form can significantly shorten the transition process of the 
metastable form of L-glutamic acid to the stable form. The reason is that the SMPT process 
of GLA is controlled by the nucleation of the stable form at the beginning and seeding the 
stable form can help overcome the rate-limiting step. As shown in Figure 5-6 and Figure 
5-7, the higher seed mass results in a faster polymorph transformation rate, owing to the 
larger surface offered for precipitation of the stable form or dissolution of the metastable 
form. Since the same solute mass will be precipitated on the surface of the seeds from the 
solution, more seeds added to the crystallizer causes smaller final crystal average size.  
 
Figure 5-6. Effect of seeds mass of stable form on the transformation process and 
crystal size distribution 
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Figure 5-7. Effect of seeds mass of metastable form on the transformation process 
and crystal size distribution 
The last property of seed evaluated in this work is seed average size. The seed mass was 
chosen as 10% of the maximum mass of the crystals. The standard deviation was 5𝜇𝑚.  
From Figure 5-9 and Figure 5-10, it is found that seeding with smaller crystals, either of 
the stable form or the metastable form, leads to a faster transformation process and smaller 
final product size. The reason is similar to that of the seed mass effect explained above.  
The smaller seeds, which have higher particle number and larger specific surface area than 
the larger seeds with the same mass, provide more precipitation sites and higher molecular 
transport rates. Schöll et al.  (Schöll et al., 2006) also found that the smaller seeds with 
identical mass cause a smaller average size of the final product, as shown in Figure 5-8.  
 
Figure 5-8. Initial and final square weighted chord length distribution of the two 
seed populations for the seeded transformation experiments at 45 C (Reprinted 
with permission from Schöll et al., 2006. Copyright @ 2006 American Chemical 
Society) 
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Figure 5-9. Effect of seeds average size of the stable form on the transformation 
process and crystal size distribution 
 
Figure 5-10. Effect of seeds average size of the stable form on the transformation 
process and crystal size distribution 
5.3.2 MSMPR crystallization 
5.3.2.1 Temperature / Residence time / Inlet concentration  
For a single MSMPR crystallization, the main variables considered are residence time, 
crystallizer temperature, and inlet concentration, whose ranges are 30-90 min, 15-35 ℃, 
25-45 g/kg (equals to the solubility of the metastable form at 47 ℃ and 63 ℃), respectively. 
As displayed in Figure 5-2(b), it takes about 4 hours to complete the solution-mediated 
polymorphic transition process of L-glutamic acid in batch crystallization. Therefore, it is 
expected that the dominant product at the steady-state is the metastable form with residence 
time less than 90 min. Only when the inlet solution is supersaturated with respect to the 
110 
 
stable form and under supersaturated to the metastable form, can the pure stable form be 
obtained in a single MSMPR process at the expense of yield. 
From Figure 5-11, the following conclusions can be drawn: 
1. The product yield and crystal size of the metastable form increase with increasing 
the inlet concentration and residence time, but decrease with the crystallizer 
temperature. 
2. Long residence time and high crystallizer temperature favor the production of the 
stable form with larger size. Inlet concentration has little effect on the mass fraction 
and size of the stable form. 
 
 
Figure 5-11. Effect of residence time/inlet concentration/temperature of MSMPR 
crystallizer on a) yield, b) the mass percentage of stable form, c) volume average size 
of the stable form and d) volume average size of stable form 
5.3.2.2 Initial conditions 
Several researchers have proven that the initial solution concentration and seed properties 
in a single MSMPR crystallizer do not impact the steady-state (Lai et al., 2015; Nicoud et 
al., 2019), because the initial solution or slurry and seeds will be washed out of the 
a) b) 
c) d) 
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crystallizer after several residence times. The simulation results displayed in Figure 5-12 
demonstrate that whatever the initial condition is, the system will reach the same steady-
state, but the start-up processes vary with the initial condition. Since the crystals produced 
during the start-up process cannot be used as a final product due to their inconsistent 
properties, the start-up optimization to shorten the stabilization time and reduce the waste 
is of great significance. 
 
Figure 5-12. The change of solution concentration with different a) initial 
concentration and b) seed properties. Residence time = 30 min, temperature =25 ℃, 
inlet concentration = 23 g/kg 
5.3.2.3 Continuous seeding 
For p-aminobenzoic acid, 𝛼 form is more stable above 15 ℃ and 𝛽-form is more stable at 
the lower temperature. In Lai et al.’s work (Lai et al., 2015), it was found that the 𝛽-form 
is the only product from a single MSMPR at 5 ℃. With the help of two-stage MSMPR, the 
authors successfully obtained 𝛼 form in the second MSMPR at 5 ℃, which received the 
seeds of 𝛼 form from the first MSMPR at 30 ℃. This study indicates that continuous 
seeding may be an effective approach to alter the steady-state in continuous crystallization. 
Hence, the possibility of altering the steady-state by continuous seeding strategy is 
evaluated numerically in this section. 
a) b) 
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Figure 5-13. The steady-state with different continuous seed mass of L-glutamic 
acid. (Residence time = 30 min, Temperature =25 ℃, Inlet concentration = 23 g/kg) 
Table 5-2. The steady-state with different continuous seed mass of L-glutamic acid 
(Residence time = 30 min, Temperature =25 ℃, Inlet concentration = 23 g/kg) 
Seed 
mass /RT 
Concentration at 
steady state(g/kg) 
Metastable produce 
mass (g/RT) 
Stable 
(g/RT) 
Stable 
form wt% 
Yield (%) 
No seed 14.03 8.88 0.11 1.2 60.2 
0.2g 13.59 3.69 5.92 61.6 63.1 
0.5g 12.83 0.37 10.30 96.5 68.2 
0.8g 12.18 0.008 11.62 99.9 72.6 
1g 11.88 0.0002 12.14 100 74.6 
The steady-state with different continuous seed mass of L-glutamic acid is shown in Figure 
5-13a and Table 5-2. As the product is the metastable form L-glutamic acid without 
continuous seeding, the stable form is continuously fed into the system. The mass fraction 
of the stable form increases remarkably with the continuous seed mass. The polymorph at 
the steady-state is altered to the pure stable form when continuous seed mass is higher than 
0.8 g/kg/RT. Taking 1 kg solvent as an example, without continuous seeding, the product 
for each residence time is 8.88 g metastable form and 0.11g stable form, whereas with 
seeding 0.2 g/RT, the product consists of 0.008 g metastable and 11.62 g stable form. This 
finding demonstrates the validity of continuous seeding on altering the product 
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polymorphism. The product yield also increases from 60.2% to 74.6% due to the extra 
surface brought in by the seeds. 
To realize the continuous seeding strategy, we can use a suspension with the desirable 
seeds as the feed of a single MSMPR (Figure 5-14), or multi-stage MSMPR, of which the 
slurry moves out from the first stage and fed to the next stage (Figure 5-15). However, 
suspension transport, especially with slow transport velocity, may lead to the blockage 
problem. Intermittent withdrawal with high transport velocity is widely used to solve the 
suspension transport issue. 
 
Figure 5-14. Schematics of a suspension-fed single MSMPR 
 
Figure 5-15. Schematics of two-stage MSMPRs 
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5.3.2.4 Intermittent withdrawal 
For intermittent withdrawal, the withdrawal frequency, the number of withdrawals taken 
during one residence time, is an important parameter. High intermittent withdrawal 
frequency makes the system closer to a continuous-in-continuous-out MSMPR crystallizer, 
but also results in slow transport. In contrast, when the frequency is as low as 0, the system 
can be regarded as batch crystallization. The main difference between the batch and 
MSMPR crystallizer is their residence time distribution (RTD), which is used to determine 
the optimal withdrawal frequency.  
Assuming the solids in suspension have the same RTD as liquids, the RTD of MSMPR 
with intermittent withdrawal can be analyzed by the step tracer method. The mass balance 
for a suspension-fed single MSMPR is 
 𝑑𝑉
𝑑𝑡
= 𝑄𝑓𝑒𝑒𝑑𝛿(𝑡 −
𝜏
𝑓
) − 𝑄𝛿(𝑡 −
𝜏
𝑓
) 
(5-14) 
 
𝑑𝑉𝐶
𝑑𝑡
= 𝑄𝑓𝑒𝑒𝑑𝛿(𝑡 −
𝜏
𝑓
)𝐶𝑓𝑒𝑒𝑑 − 𝑄𝛿(𝑡 −
𝜏
𝑓
)𝐶 (5-15) 
The mass balances for a two-stage MSMPR system are: 
 
𝑑𝑉1
𝑑𝑡
=  𝑄𝑓𝑒𝑒𝑑 − 𝑄1𝛿(𝑡 −
𝜏1
𝑓
) (5-16) 
 
𝑑𝑉2
𝑑𝑡
=  𝑄1𝛿(𝑡 −
𝜏1
𝑓
) − 𝑄2𝛿(𝑡 −
𝜏2
𝑓
) (5-17) 
 
𝑑𝑉1𝐶1
𝑑𝑡
= 𝑄𝑓𝑒𝑒𝑑𝐶𝑓𝑒𝑒𝑑 − 𝑄1𝛿(𝑡 −
𝜏1
𝑓
)𝐶1 (5-18) 
 
𝑑𝑉2𝐶2
𝑑𝑡
= 𝑄1𝛿(𝑡 −
𝜏1
𝑓
)𝐶1 − 𝑄2𝛿(𝑡 −
𝜏2
𝑓
)𝐶2 (5-19) 
in which subscript 1 and 2 refer to the stage number. 𝑄𝑓𝑒𝑒𝑑 , 𝑄1 and 𝑄2 are the volumetric 
flow rate from feed tank, 1st MSMPR and 2nd MSMPR.  For a continuous-in-continuous-
out MSMPR system, they should be the same to keep the solution volume constant. 𝑉 is 
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solution volume, 𝑡 is time, 𝜏 is residence time, 𝐶 is solution concentration, 𝛿 is Dirac delta 
function and 𝑓 is withdrawal frequency. 
 
Figure 5-16. Normalized Residence time distribution of suspension-fed single 
MSMPR with different withdrawal frequency (1, 5, 10 and 20) 
Intermittent withdrawal for the feed tank or 1st MSMPR means the intermittent seeding for 
the following crystallizer. Therefore, the conclusion of the intermittent withdrawal is the 
same as the intermittent feeding. The effect of intermittent frequency 𝑓 on the RTD for two 
continuous seeding configuration is shown in Figure 5-16 and  Figure 5-17. The results 
show that RTD of intermittent operation is very close to continuous operation when the 
frequency is greater than 10. The sensitivity analysis of the optimal intermittent frequency 
is performed with normalized average residence time, which is defined as the ratio between 
the average residence time of intermittent operation and residence time of continuous 
operation. From Figure 5-18, it is noted that the intermittent operation has higher average 
residence time than continuous operation when the intermittent frequency is low, and the 
optimal frequency is ten times per residence time.  
a) b) 
c) d) 
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 Figure 5-17. Normalized Residence time distribution of 2nd crystallizer of two-stage 
MSMPR with different withdrawal frequency (1, 5, 10 and 20) 
 
 
Figure 5-18. Normalized average residence time with different withdrawal 
frequency 
a) b) 
c) d) 
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5.3.2.5 Suspension transport velocity 
Before conducting the experiments of MSMPR, it is important to decide which suspensions 
removal strategy, intermittently or continuously, is preferred. The key parameter is the 
suspension transport velocity. To transfer the suspensions successfully without blockage 
issues, the suspension velocity in the tube should be greater than the horizontal velocity to 
carry the particles to move forward. For a 200 mL MSMPR crystallizer whose residence 
time is 30 min, the minimum horizontal velocity with 3.2-mm diameter tube is  (Heywood, 
1999; Yang et al., 2017) 
𝑈ℎ𝑜𝑟𝑖𝑧𝑜𝑛𝑡𝑎𝑙 = 𝐹 [2𝑔 (
𝜌𝑐
𝜌𝐿
− 1) 𝐷] (
𝑑𝑐
𝐷𝑖
)
1
6
 
(5-20) 
= 1.4 [2 ∗ 9.8 (
1540
1000
− 1) × 3.2 × 10−3] (
50 × 10−6
3.2 × 10−3
)
1
6
= 0.0237 𝑚/𝑠   
where F is the Durand factor in the range of 0.4 and 1.4 (1.4 is used here), 𝐷𝑖 is the inner 
diameter of the tube (3.2 mm). 𝜌𝑐 and 𝜌𝐿 are crystal and fluid densities, which are 1540 
kg/m3 for L-Glutamic acid and 1000 kg/m3 for water. 𝑑𝑐 is the crystal diameter (50-μm 
was used in the calculation), and 𝑔 is the gravitational acceleration, 9.8 m/s2. 
The velocity with continuous operation via a 3.2 mm tube is around 0.014 m/s, smaller 
than the minimum horizontal velocity, so the intermittent strategy with a peristaltic pump 
(Masterflex L/S; Cole Palmer, Vernon Hills, IL) was adopted in our lab. With a home-
made planetary gear (Figure 5-19), the suspension line velocity can reach 0.55 m/s, which 
is much greater than the minimum horizontal velocity. It is worth pointing out that the 
maximum velocity of a designated peristaltic pump can be increased further by increasing 
the outer diameter or the transmission ratio, the ratio of the diameters of the sun gear and 
planetary gear. 
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Figure 5-19. Home-made planetary gear used as the pump head 
High velocity also can shorten the residence time of the particles in the tube, so to prevent 
the crystal precipitation and clogging problems. The average time for particles settling in 
the tube should be shorter than the crystal residence time in the tube. The residence time 
for 1m tube is  
1 𝑚
0.55 𝑚/𝑠
= 1.83 𝑠. 
Particle terminal velocity is  
𝑈𝑣𝑒𝑡𝑖𝑐𝑎𝑙 =
𝑔(𝜌𝑐 − 𝜌𝐿)𝑑𝑐
2
18𝜈
=
9.8(1540 − 1000)(50 × 10−6)2
18 × 8.9 × 10−4
= 8.26 × 10−4 𝑚/𝑠 
(5-21) 
where 𝜈 is the fluid dynamic viscosity. The Reynolds number of the particles is  
 𝑅𝑒𝑝 =
𝑑𝑐𝑈𝑣𝑒𝑡𝑖𝑐𝑎𝑙
𝜈
=
50 × 10−6 × 8.26 × 10−4
8.9 × 10−3
= 0.046 < 0.1 (5-22) 
hence, the fluid is in the laminar flow regime, which means Stoke’s law (Eq. (5-21)) is 
valid here.  
The average time for particles settling in the tube is =
1.6×10−3 𝑚
8.26×10−4 𝑚/𝑠
= 1.94 𝑠, greater than 
the residence time, which ensures the crystals leave the transfer tube before they precipitate. 
In our laboratory, a 200 mL MSMPR crystallizer and a one-meter long transfer tube with 
3.2-mm diameter were used to conduct the single MSMPR crystallization. The system with 
intermittent removal can operate successfully without any clogging and particle settling 
issues for 10 residence times. 
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5.4 Conclusions 
Table 5-3. The effects of the operating conditions in batch crystallization 
(+ and – presents positive and negative effect, NA is not applicable) 
 
Initial 
concentration 
Cooling 
power 
number 
wt.% of the 
stable form 
in seeds 
Seed 
mass 
Seed 
size 
Stable size - + - - + 
Transition time - NA - - + 
 
Table 5-4. The effects of the operating conditions in MSMPR crystallization 
(+ and – presents positive and negative effect) 
 
Residence 
time 
Inlet 
concentration 
Temperature of 
crystallizer 
Yield + + - 
Mass fraction of stable 
form 
+ little + 
Stable size + little + 
Metastable size + + - 
The effects of the operating conditions in batch and MSMPR crystallization on the crystal 
properties with L-glutamic acid water were investigated thoroughly and summarized in  
Table 5-3 and Table 5-4. Owing to the solution-mediated polymorphic transformation, it 
is easier to produce the stable form in batch crystallization. Long transition time provided 
the chance to remove the metastable before the transition happens. The initial concentration 
and seeds mass and polymorphic form have no impact on the steady-state product quality 
of an MSMPR. It is proven that the continuous seeding strategy can alter the steady-state, 
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including polymorphism. To avoid the blocking issue, the intermittent seeding and 
withdrawal method were suggested. The optimal intermittent frequency was set to 10 by 
the sensitivity analysis of the normalized average residence time. With the intermittent 
method, the suspension transport velocity is higher than the minimum horizontal particle 
velocity in the tube and the suspension residence time in the transfer tube is less than the 
particle settling time, which guarantees the success of suspension transport.  
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6 Conclusions and Recommendations 
6.1 Conclusions  
In this work, the polymorphism phenomenon in crystallization processes was studied 
experimentally and numerically. Clear guidelines were developed to produce the desired 
polymorph with suitable properties in both batch and continuous crystallization processes. 
The main conclusions discussed in previous chapters are summarized here. 
6.1.1 Thermodynamic and dynamic study 
Polymorph screening is a major challenge in pharmaceutical manufacturing, and having 
access to the accurate thermodynamic and kinetic parameters is vital for crystallization 
design and control. Since the imatinib mesylate properties, particularly those related to the 
crystallization process, were lacking in the literature, α-form and 𝛽-form imatinib mesylate 
were fully characterized in Chapter 2.  
With the aid of ultraviolet-visible spectroscopy, the solubilities of both forms were 
determined in various solvents, revealing that α-form and 𝛽-form imatinib mesylate are 
enantiotropically related. Then, the solution-mediated polymorphic transformation process 
from metastable 𝛼-form to stable 𝛽-form was studied in methanol solution with the in-situ 
Raman spectroscopy and conductivity meter. Finally, the nucleation and growth rates of 
𝛽-form of imatinib mesylate were estimated with MATLAB optimization function. 
The findings of this chapter paved the path for future research on designing the 
crystallization process for imatinib mesylate, and general guidelines for other active 
pharmaceutical ingredients. 
6.1.2 Crystallization process monitoring 
In Chapter 3, a methodology was developed to determine the solution concentration and 
solids concentration simultaneously and quantitatively using Raman spectroscopy. 
Commonly, ATR-FTIR is used to determine the solution concentration. But ATR-FTIR is 
not applicable, if materials have low infrared activity or low solubility. The main difficulty 
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involved in using Raman is that the spectrum is a multivariable function of solution 
concentration, solids concentration and temperature. Consequently, robust mathematical 
techniques have been employed to decouple the data related to the solution concentration 
and solids concentration. 
Different pre-processing methods (spectra range selection, baseline removal, direct 
orthogonal signal correction-DOSC) and multivariable analysis techniques (characteristic 
peaks regression (CPR), principal component regression (PCR), partial least squares 
regression (PLSR) and artificial neural network (ANN)) were applied and compared based 
on the root mean squared error (RMSE). 
It has been found that the direct orthogonal signal correction pre-processing can improve 
the fitting performance of the linear regression models (CPR, PCR, and PLSR), but not for 
ANN. In the case of weak signals, the ANN model showed better prediction ability than 
the linear models owing to its non-linear prediction ability. We showed that Raman 
spectroscopy is not only capable of measuring the solids concentration, but also able to 
provide solution concentration, in a comparable manner to the IR technique.  
6.1.3 Polymorph prediction based on the relative kinetics  
From the literature, it is found that different polymorphic systems have different preferred 
polymorph in batch and MSMPR crystallization. For paracetamol, the stable form was the 
only product in either metastable-form-seeded batch crystallization or MSMPR (mixed 
suspension and mixed product removal) crystallization (Nicoud et al., 2019a, 2019b). For 
L-glutamic acid, the stable form was obtained at 45 °C in MSMPR or by SMPT process 
within six hours in a batch crystallizer, while the metastable form was produced from fast 
cooling batch crystallization or MSMPR crystallization at 25 °C (Lai et al., 2014). For p-
aminobenzoic acid, the metastable form was the preferred polymorph as it took two days 
to complete the solution-mediated polymorphism transform process at 5 °C, while the 
stable form was the product with MSMPR crystallization at 5 °C (Lai et al., 2015). 
These phenomena indicate that the kinetics contributes significantly to the polymorphic 
outcome. However, the effects of polymorph relative kinetics and the strategy to crystallize 
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the desired polymorph have been investigated rarely, especially in continuous 
crystallization.  
In Chapter 4, the impacts of relative nucleation and growth kinetics of the two polymorphs 
on the polymorphic outcome were studied numerically in batch and MSMPR 
crystallization. Two dimensionless numbers, 𝑅𝑘𝑏  and 𝑅𝑘𝑔 , were defined as the ratios 
between the nucleation rate constants and growth rate constants of two polymorphs:  
 𝐵 = 𝑘𝑏(𝑆 − 1)
𝑏  
 
𝑅𝑘𝑏 =
𝑘𝑏𝑠𝑡𝑎𝑏𝑙𝑒
𝑘𝑏𝑚𝑒𝑡𝑎𝑠𝑡𝑎𝑏𝑙𝑒
 
 
 𝐺 = 𝑘𝑔(𝑆 − 1)
𝑔   
 
𝑅𝑘𝑔 =
𝑘𝑔𝑠𝑡𝑎𝑏𝑙𝑒
𝑘𝑔𝑚𝑒𝑡𝑎𝑠𝑡𝑎𝑏𝑙𝑒
 
 
where 𝑘𝑏  is the nucleation rate constant [#/s/kg solvent], 𝑘𝑔 is growth rate constant [m/s], 
𝑏 and 𝑔 are the exponents, and 𝑆 is the supersaturation, 
 
𝑆 =  
𝐶(𝑡)
𝐶∗
 
 
where 𝐶 is the solution concentration and  𝐶∗ is the solubility. 
An indicator,  𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
, was proposed to analyze the possibility of producing the 
metastable form with 99 wt% purity in batch crystallization. It has been found that 𝑅𝑘𝑔 ∙
𝑅𝑘𝑏
1/3
< 0.22 is required to have at least 10 min time window for the removal of the 
metastable form from the solution before the polymorphism transition process happens. In 
MSMPR crystallizer, this indicator was used to check whether the operating conditions 
(crystallizer temperature, residence time, and inlet concentration) can alter the steady-state 
polymorph. When 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
 is greater than 1 or less than 0.1, the dominant product is 
either the stable form or metastable form, and the operating conditions cannot effectively 
control the product polymorph. In such a case, changing the solvent and adding additives 
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are alternative methods to crystallize the other polymorph by influencing the kinetic ratio 
of two polymorphs. 
This work provides a general approach to determine the optimal crystallization operation 
to harvest the desired polymorph of a bi-polymorph system, when their relative kinetics 
are known. Concretely speaking, a) the stable form with slow kinetics (𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
< 0.1) 
cannot be easily obtained from MSMPR crystallization, but can be produced by the SMPT 
process in batch crystallization; b) the prerequisite for producing the high purity metastable 
form in batch crystallization is that the metastable form to have fast relative kinetics (𝑅𝑘𝑔 ∙
𝑅𝑘𝑏
1/3
< 0.22 ); c) only when 𝑅𝑘𝑔 ∙ 𝑅𝑘𝑏
1/3
is in the range of 0.1 to 1, the operating 
conditions can alter the polymorphic outcome in MSMPR crystallization. 
6.1.4 Crystallization process design  
After studying the crystal kinetics, we investigated the operating conditions and strategies 
of the batch and MSMPR crystallization. The findings below offer general guidance for 
designing a crystallization process. L-glutamic acid - water was selected as the model 
system in this work. 
In the batch cooling crystallization, the impacts of the initial concentration, cooling profile, 
polymorphic form of the seeds, seed mass and seed size on the crystal size and 
polymorphism transformation time were studied. A longer polymorphism transformation 
time provides a higher chance to produce the metastable form with the batch crystallization. 
The simulation results show that the crystal size and polymorphic transition time decrease 
with increasing the initial concentration, the mass fraction of the stable form seeds and seed 
mass; but increase with increasing the seed size.  
In a single MSMPR crystallization, the impacts of the residence time, crystallizer 
temperature, and inlet concentration on the product yield, crystal polymorph, stable form 
average size and metastable form average size were studied. It is shown that the product 
yield and size of metastable form increase with an increase in the residence time and feed 
concentration, but decrease with increasing the crystallizer temperature. The mass fraction 
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and crystal size of the stable form increase with increasing the residence time and 
crystallizer temperature, but are not affected by the feed concentration.  
Since the initial solution and seeds in MSMPR will be washed out of the crystallizer after 
several residence times and do not impact the steady-state, the continuous seeding strategy 
was proposed and realized with a suspension-fed single MSMPR or two-stage MSMPRs. 
It has been proven numerically that the continuous seeding could alter the steady-state 
polymorphic outcome of the product. 
Then, the intermittent seeding and withdrawal method was adopted to avoid the blocking 
issue during suspension transport. Its validity was demonstrated by comparing the 
suspension transport velocity and minimum horizontal particle velocity, as well as the 
suspension residence time in the transfer tube and the particle settling time. With the 
sensitivity analysis of the normalized average residence time, we found the optimal 
intermittent frequency is 10 times per residence time. 
6.2 Recommendations  
The studies conducted and reported in this thesis have shown the significance of the 
thermodynamic and kinetic parameters, development of process analytic technologies, and 
numerical modeling in crystallization engineering. Future researches can emphasize the 
potential improvements in process analytical technologies (PATs) and pursue innovation 
in combining the crystallization system with the modeling tools. 
Here are some recommendations for future work: 
• The crystallization kinetic models are reported in different formats and the 
parameters for the same systems may vary greatly. This is because the kinetic 
models are often empirical and many factors and disturbances are not considered 
e.g., stirring rate and the crystallizer geometry. Brown et al. (Brown et al., 2020)  
have collected the nucleation and growth kinetic parameters from 185 papers. This 
database should be regularly updated with the contribution of the researchers with 
some standardized models so that the industry can overcome the blind spots in the 
current modeling techniques in the future. 
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• It is demonstrated that Raman spectroscopy can be used for online solution 
concentration and slurry density measurement. More work on the estimation of the 
nucleation, growth, dissolution parameters and process monitor can be carried out 
by Raman spectroscopy alone, especially when the crystallizer is small. Also, 
measuring the concentration, polymorphism, and solids concentration from the 
same location can improve the modeling accuracy. 
  
• Solving the hyperbolic mathematical model of the population balance equation 
numerically showed various difficulties. For example, there are many different 
solving schemes such as upwind, high-resolution, and collocation methods and all 
of them are showing unique numerical properties. Repeating the programming and 
verification work in creating one of these algorithms that fits specific requirements 
can be time-consuming and error-prone. Despite many open-source projects and 
commercial software focusing on solving the PBE for a crystallization system, at 
the time of writing of this thesis it was still difficult to find a software package that 
is highly customizable, easy to learn, and efficient. Our group has initiated the 
project working on an open-source re-useable PBE solver implemented in 
MATLAB/Simulink that will support the modeling of batch/continuous systems, 
polymorphic transformation, agglomeration and breakage, and customizable 
kinetics. This work will help the researcher to start with a reproducible and full-
featured platform in crystallization modeling. 
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Appendices 
In appendix A, the MATLAB codes used to model the batch and MSMPR crystallization 
process are summarized. Appendix B includes the MATLAB codes about the pre-
processing methods and multivariable analysis techniques, which were applied to analyze 
the Raman spectroscopy in Chapter 3. The procedure of principal component analysis and 
partial least squares regression are described in appendix C. Appendix D presents the 
permissions to use copyrighted materials in Chapter 2, Chapter 3 and Chapter 5. 
Appendix A. MATLAB codes for the crystallization process 
modeling 
A.1. Fundamental data 
A.1.1 Solubility of stable form 
function C_star = solubility(T) 
 C_star = (7.644*10^-3.*T.^2 - 1.165*10^-1.*T + 6.222)/1000; 
 
function C_star = solubility_1(T) 
C_star = (8.437*10^-3.*T.^2 + 3.032*10^-2.*T + 4.564)/1000; 
 
A.1.2 Birth, growth and dissolution rate 
function B = Birth(kb,kb2,b,T,C,m3,rho_solvent) 
B =0; 
C_star = solubility(T); 
if C>C_star 
    B = ((abs(C./C_star-1)).^(b).*(kb+kb2.*(m3)^(2/3))./rho_solvent); 
    B(isnan(B))=0; 
end 
 
function G = growth(kg1,kg2,T,C) 
G=0; 
C_star = solubility(T); 
if C>C_star 
    G = kg1.*abs(C./C_star-1).^(kg2); 
    G(isnan(G))=0; 
end 
 
function D = Dissolution_1(kd_1,T,C,m3) 
D = 0; 
C_star_1 = solubility_1(T); 
132 
 
if (C<C_star_1 && m3>0) 
    D = kd_1.*(abs(C./C_star_1-1)); 
end 
 
A.1.3 Size distribution of seeds 
function csd = fun_csd(mass,ave_size,sd,kv,rho,L) 
CSD_pdf =normpdf(L,ave_size,sd); 
stable_lamda= mass./(rho*kv*trapz(L,CSD_pdf .*L.^3)); 
csd = stable_lamda*CSD_pdf;   % popolation density--unit-#/m/kg solvent 
 
A.2. Batch crystallizer 
A.2.1 Main code 
clc 
clear 
dbstop if error 
  
%--------- Kinetic parameters for metastable polymorph 
kb_1 = 1e8;     kb_12 = 1e12;      b_1 = 2;    kg_1 = 1e-8;    g_1 = 1;    kd_1 =2.2e-6; 
  
%--------- Kinetic parameters for stable polymorph 
kb = 1*kb_1;    kb2 = 1*kb_12;   b = b_1;    kg = kg_1;        g = g_1;    kd = 0; 
  
kv_stable =  0.48;            rho_stable = 1540;            %kg/m3 
kv_metastable = 0.48;   rho_metastable = 1540;   %kg/m3 
rho_solvent = 1000;       v_solvent=1;                       %kg/m3 & m3 
  
%---------------------Time and length grid -------------------------------- 
ntime=360; batch_time = 1*3600; delta_t = batch_time/ntime;  %seconds 
nl=1000; L0=0;Lmax =1000*10^-6; delta_L=(Lmax-L0)/nl;  
L=((L0+delta_L/2):delta_L:(Lmax-delta_L/2))';  % length grid-m 
  
%---------------------Temperature and concentration------------------------ 
C_initial=solubility_1(60); 
T_initial=25; T_final=25; 
  
%---------------- Seeding parameters for stable poylmorph ----------------- 
CSD_stable(1,:) = fun_csd(0e-3,100e-6,10e-6,kv_stable,rho_stable,L); 
CSD_metastable(1,:)= fun_csd(0e-3,100e-6,10e-6,kv_metastable,rho_metastable,L); 
  
miu = trapz(L,CSD_stable'.*L.^(0:5)); 
miu_1 = trapz(L,CSD_metastable'.*L.^(0:5)); 
  
N0 = [ miu_1 miu C_initial]; 
result(1,1:13) = N0; 
133 
 
  
B_stable = zeros(ntime,1); B_metastable = zeros(ntime,1);  %#/s/kg 
Dissolution_stable = zeros(ntime,1); Dissolution_metastable = zeros(ntime,1);  %m/s 
Growth_stable = zeros(ntime,1); Growth_metastable = zeros(ntime,1);  %m/s 
  
for i=1:ntime 
     
    result(i,:) = N0; 
    B_stable(i) = Birth(kb,kb2,b,T(i),result(i,13),result(end,10),rho_solvent); 
    B_metastable(i) = Birth_1(kb_1,kb_12,b_1,T(i),result(i,13),result(end,4),rho_solvent); 
    Dissolution_stable(i) = Dissolution(kd,T(i),result(i,13)); 
    Dissolution_metastable(i) = Dissolution_1(kd_1,T(i),result(i,13),result(end,4)); 
    Growth_stable(i) = growth(kg,g,T(i),result(i,13)); 
    Growth_metastable(i) = growth_1(kg_1,g_1,T(i),result(i,13)); 
     
    if i>1 
        CSD_stable(i,:) = csd_fvm(CSD_stable(i-1,:),(Growth_stable(i)-Dissolution_stable(i)), ... 
B_stable(i),nl,delta_L,delta_t); 
        CSD_metastable(i,:) = csd_fvm(CSD_metastable(i-1,:),(Growth_metastable(i)- ... 
Dissolution_metastable(i)),B_metastable(i),nl,delta_L,delta_t); 
    end 
     
    [t N] = 
ode45(@batch_fun_miu_fvm,[0,delta_t],N0,[],T(i),rho_stable,kv_stable,rho_metastable, ... 
kv_metastable,rho_solvent,kb,b,kb_1,b_1, kg,g,kg_1,g_1, kd,kd_1, kb2,kb_12); 
     
    N(N<0)=0; 
    N0 = real(N(end,:))'; 
    N0(1) = sum(CSD_metastable(i,:))*delta_L; N0(7) = sum(CSD_stable(i,:))*delta_L; 
end 
  
Concentration= result(:,13); 
Supersaturation_stable = Concentration'./solubility(T(1:ntime)); 
Supersaturation_metastable = Concentration'./solubility_1(T(1:ntime)); 
  
Number_ave_size_stable = result(:,8)./result(:,7)*10^6; 
Number_ave_size_metastable = result(:,2)./result(:,1)*10^6; 
Volume_ave_size_stable = result(:,11)./result(:,10)*10^6; 
Volume_ave_size_metastable = result(:,5)./result(:,4)*10^6; 
Mass_stable_form = rho_stable/rho_solvent*kv_stable*1000*result(:,10); 
Mass_metastable_form = rho_metastable/rho_solvent*kv_metastable*1000*result(:,4); ... 
mass_percent_stable 
=Mass_stable_form./(Mass_metastable_form+Mass_stable_form);mass_percent_stable(end); 
yield = 1-Concentration./C_initial; 
  
Mass_balance = C_initial + rho_metastable*kv_metastable*miu_1(4) + rho_stable*kv_stable*... 
miu(4) - ( Mass_metastable_form(end) + Mass_stable_form(end) + result(end,13)) 
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A.2.2 Solving the PBE with Finite volume method 
function csd = csd_fvm(csd_pre,G,B,nl,deltaL,t) 
 
csd = csd_pre; 
if G>0 
    csd(1) = B/G; 
     
    csd_pre =[B/G, csd_pre, 0]; 
    theta_n = (csd_pre(2:nl+1) - csd_pre(1:nl))./(csd_pre(3:nl+2) - csd_pre(2:nl+1)); 
     
    phi_n = (abs(theta_n)+theta_n)./(1+abs(theta_n)); 
    phi_n(isnan(phi_n)) = 0; 
     
    csd(2:nl) = csd_pre(3:nl+1) - G*t/deltaL*((csd_pre(3:nl+1) - csd_pre(2:nl)))- G*t/(2*deltaL)*(1-
G*t/(deltaL)).*((csd_pre(4:nl+2)-csd_pre(3:nl+1)).*phi_n(2:nl)-(csd_pre(3:nl+1)-csd_pre(2:nl)).* 
phi_n(1:nl-1)); 
     
elseif  G<0 
    csd_pre =[0, flip(csd_pre), 0];  G = abs(G); 
    theta_n = (csd_pre(2:nl+1) - csd_pre(1:nl))./(csd_pre(3:nl+2) - csd_pre(2:nl+1)); 
     
    phi_n = (abs(theta_n)+theta_n)./(1+abs(theta_n)); 
    phi_n(isnan(phi_n)) = 0; 
     
    csd(2:nl) = csd_pre(3:nl+1) - G*t/deltaL*((csd_pre(3:nl+1) - csd_pre(2:nl)))- G*t/(2*deltaL)*(1-
G*t/(deltaL)).*((csd_pre(4:nl+2)-csd_pre(3:nl+1)).*phi_n(2:nl)-(csd_pre(3:nl+1)-csd_pre(2:nl)).* 
phi_n(1:nl-1)); 
     
    csd(1) = 0;  csd = flip(csd);     
end 
  
csd = csd'; 
end 
A.2.3 Solving the mass balance and PBE with method of moment 
function 
dN=batch_fun_miu_fvm(~,N,T,rho_crystal,kv_stable,rho_crystal_1,kv_metastable,rho_solvent,..
. kb,b,kb_1,b_1, kg,g,kg_1,g_1, kd,kd_1, kb2,kb_12) 
  
dN = zeros(13,1); 
  
g_d_1 = growth_1(kg_1,g_1,T(1),N(13))-Dissolution_1(kd_1,T(1),N(13),N(4)); 
g_d = growth(kg,g,T(1),N(13))-Dissolution(kd,T(1),N(13)); 
  
dN(1) =  Birth_1(kb_1,kb_12,b_1,T(1),N(13),(N(4)),rho_solvent);    
dN(2:6) =  (1:5)'.*g_d_1.*N(1:5);  
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dN(7) = Birth(kb,kb2,b,T(1),N(13),(N(10)),rho_solvent);   
dN(8:12) = (1:5)'.*g_d.*N(7:11); 
 
dN(13)= -3.*rho_crystal_1.*kv_metastable.*g_d_1.*(N(3))... 
               -3.*rho_crystal.*kv_stable.*g_d.*(N(9))... 
        -rho_crystal_1.*kv_metastable.*dN(1).*(0e-6)^3-rho_crystal.*kv_stable.*dN(7).*(0e-6)^3;     
A.3 MSMPR crystallizer 
A.3.1 Main code 
clc 
clear 
dbstop if error 
  
kb_1 = 1e8; kb_12 = 1e12; b_1 = 2;  kg_1 = 1e-8;    g_1 = 1;    kd_1 =2.2e-6; 
kb = 1*kb_1;    kb2 = 1*kb_12;   b = b_1;    kg = kg_1;        g = g_1;    kd = 0; 
  
kv_stable =  0.48; rho_stable = 1540; 
kv_metastable =.48; rho_metastable = 1540; 
rho_solvent = 1000;v_solvent=1; 
 
residence_time =60*60; rtnumber=20; timegrid = 1440; 
delta_t = residence_time*rtnumber/timegrid; 
  
nl=1000; L0=0; LN =1000*10^-6; delta_L=(LN-L0)/nl; L=((L0+delta_L/2):delta_L:(LN-delta_L/2))'; 
  
T_msmpr=25; T = ones(timegrid+1,1)*T_msmpr; 
C_inlet=solubility_1(60); C_initial =solubility_1(T_msmpr); 
 
CSD_stable(1,:) = fun_csd(0e-3,100e-6,10e-6,kv_stable,rho_stable,L); 
CSD_metastable(1,:)= fun_csd(0e-3,100e-6,10e-6,kv_metastable,rho_metastable,L); 
  
miu = trapz(L,CSD_stable'.*L.^(0:5)); 
miu_1 = trapz(L,CSD_metastable'.*L.^(0:5)); 
  
N0 = [ miu_1 miu C_initial]; 
result(1,1:13) = N0; 
 
B_stable = zeros(timegrid,1); B_metastable = zeros(timegrid,1);  %#/s/kg 
Dissolution_stable = zeros(timegrid,1); Dissolution_metastable = zeros(timegrid,1);  %m/s 
Growth_stable = zeros(timegrid,1); Growth_metastable = zeros(timegrid,1);  %m/s 
  
for i=1:timegrid 
     
    result(i,:) = N0; 
     
    B_stable(i) = Birth(kb,kb2,b,T(i),result(i,13),result(end,10),rho_solvent); 
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    B_metastable(i) = Birth_1(kb_1,kb_12,b_1,T(i),result(i,13),result(end,4),rho_solvent); 
    Dissolution_stable(i) = Dissolution(kd,T(i),result(i,13)); 
    Dissolution_metastable(i) = Dissolution_1(kd_1,T(i),result(i,13),result(end,4)); 
    Growth_stable(i) = growth(kg,g,T(i),result(i,13)); 
    Growth_metastable(i) = growth_1(kg_1,g_1,T(i),result(i,13)); 
     
     
     if i>1 
        CSD_stable(i,:) = msmpr_csd_fvm(CSD_stable(i-1,:),(Growth_stable(i)-Dissolution_stable(i)), 
B_stable(i),nl,delta_L,delta_t,residence_time); 
        CSD_metastable(i,:) = msmpr_csd_fvm(CSD_metastable(i-1,:),(Growth_metastable(i)-
Dissolution_metastable(i)),B_metastable(i),nl,delta_L,delta_t,residence_time); 
    end 
     
    [t N] = ode45(@msmpr_miu_fvm,[0,delta_t],N0,[],T(i),rho_stable,kv_stable,rho_metastable, 
kv_metastable,rho_solvent,kb,b,kb_1,b_1, kg,g,kg_1,g_1, kd,kd_1, kb2,kb_12,residence_time, 
C_inlet); 
     
    N(N<0)=0; 
    N0 = real(N(end,:))'; 
    N0(1) = sum(CSD_metastable(i,:))*delta_L; N0(7) = sum(CSD_stable(i,:))*delta_L; 
end 
  
Concentration= result(:,13); 
Supersaturation_stable = Concentration'./solubility(T(1:ntime)); 
Supersaturation_metastable = Concentration'./solubility_1(T(1:ntime)); 
  
Number_ave_size_stable = result(:,8)./result(:,7)*10^6; 
Number_ave_size_metastable = result(:,2)./result(:,1)*10^6; 
Volume_ave_size_stable = result(:,11)./result(:,10)*10^6; 
Volume_ave_size_metastable = result(:,5)./result(:,4)*10^6; 
Mass_stable_form = rho_stable/rho_solvent*kv_stable*1000*result(:,10); 
Mass_metastable_form = rho_metastable/rho_solvent*kv_metastable*1000*result(:,4); 
mass_percent_stable 
=Mass_stable_form./(Mass_metastable_form+Mass_stable_form);mass_percent_stable(end); 
yield = 1-Concentration./C_initial; 
  
Mass_balance = C_inlet +rho_metastable*kv_metastable*miu_1(4) +       
rho_stable*kv_stable*miu(4)- (Mass_metastable_form(end) + Mass_stable_form(end) + 
result(end,13)) 
A.3.2 Solving the PBE with Finite volume method 
function csd = msmpr_csd_fvm(csd_pre,G,B,m,deltaL,t,RT) 
  
csd = csd_pre; 
if G>0 
    csd(1) = B/G - csd(1)*t./RT; 
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    csd_pre =[B/G, csd_pre, 0]; 
    theta_n = (csd_pre(2:m+1) - csd_pre(1:m))./(csd_pre(3:m+2) - csd_pre(2:m+1)); 
     
    phi_n = (abs(theta_n)+theta_n)./(1+abs(theta_n)); 
    phi_n(isnan(phi_n)) = 0; 
     
    csd(2:m) = csd_pre(3:m+1) - G*t/deltaL*((csd_pre(3:m+1) - csd_pre(2:m)))- G*t/(2*deltaL)*(1-
G*t/(deltaL)).* ((csd_pre(4:m+2)-csd_pre(3:m+1)).*phi_n(2:m)-(csd_pre(3:m+1)-csd_pre(2:m)).* 
phi_n(1:m-1))-csd(2:m)*t./RT; 
     
elseif  G<0 
    csd_pre =[0, flip(csd_pre), 0];  G = abs(G); 
    theta_n = (csd_pre(2:m+1) - csd_pre(1:m))./(csd_pre(3:m+2) - csd_pre(2:m+1)); 
     
    phi_n = (abs(theta_n)+theta_n)./(1+abs(theta_n)); 
    phi_n(isnan(phi_n)) = 0; 
     
    csd(2:m) = csd_pre(3:m+1) - G*t/deltaL*((csd_pre(3:m+1) - csd_pre(2:m)))- G*t/(2*deltaL)*(1-
G*t/(deltaL)).*((csd_pre(4:m+2)-csd_pre(3:m+1)).*phi_n(2:m)-(csd_pre(3:m+1)-csd_pre(2:m)).* 
phi_n(1:m-1))-csd(2:m)*t./RT; 
     
    csd(1) = 0;  csd = flip(csd);   
end 
  
csd = csd'; 
end 
A.3.3 Solving the mass balance and PBE with method of moment 
function 
dN=msmpr_miu_fvm(~,N,T,rho_crystal,kv_stable,rho_crystal_1,kv_metastable,rho_solvent, 
kb,b,kb_1,b_1, kg,g,kg_1,g_1, kd,kd_1, kb2,kb_12,  rt, c0) 
 
dN = zeros(13,1); 
  
g_d_1 = growth_1(kg_1,g_1,T(1),N(13))-Dissolution_1(kd_1,T(1),N(13),N(4)); 
g_d = growth(kg,g,T(1),N(13))-Dissolution(kd,T(1),N(13)); 
  
dN(1) =  Birth_1(kb_1,kb_12,b_1,T(1),N(13),(N(4)),rho_solvent)- N(1)/rt ;    
dN(2:6) =  (1:5)'.*g_d_1.*N(1:5)-N(2:6)/rt;  
  
dN(7) = Birth(kb,kb2,b,T(1),N(13),(N(10)),rho_solvent)-N(7)/rt; 
dN(8:12) = (1:5)'.*g_d.*N(7:11)-N(8:12)/rt; 
 
dN(13)= -3.*rho_crystal_1.*kv_metastable.*g_d_1.*(N(3))... 
        -3.*rho_crystal.*kv_stable.*g_d.*(N(9))... 
        -rho_crystal_1.*kv_metastable.*dN(1).*(0e-6)^3.... 
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        -rho_crystal.*kv_stable.*dN(7).*(0e-6)^3+(c0 - N(13))/rt; 
     
Appendix B. Matlab codes for Raman data preprocessing and 
regression 
B.1. Preprocessing methods 
% read Raman spectrum (.spc file) 
SPCStruct = tgspcread('XXX.spc'); 
wnAxis = SPCStruct.X; 
timeAxis = SPCStruct.Z; 
RamanData = SPCStruct.Y'; 
  
% spectra range selection (1825 cm-1 to 100 cm-1) 
RamanData_rs = RamanData(:,1600:3326); 
  
% Baseline removal 
RamanData_br = msbackadj((1:3326), RamanData); 
  
% Direct orthogonal signal correction  
RamanData_dosc = dosc(RamanData,Concentration,50,1e-3); 
% dosc function was downloaded from  
% http://www.bdagroup.nl/content/Downloads/software/software.php 
B.2. Multivariable analysis techniques 
B.2.1 Characteristic peaks regression (CPR) 
[pks, locs] = findpeaks(Input_fit,'MinPeakProminence',50);  
 
[Input_std_peak, X_mu, X_sigma] = zscore(Input_peak(:,[1,locs]));  
[Conc_std, Y_mu, Y_sigma] = zscore(Conc);  % standardization 
 
peak_model = fitlm(Input_std_peak, Conc_std); 
Conc_Pred_peak = peak_model.predict((Input_Validation(:,locs) - X_mu)./X_sigma) .* Y_sigma + 
Y_mu; 
MSE_peak = immse(Conc_Exp,Conc_Pred_peak); 
B.2.2 CPR + Artificial neural network (ANN) 
trainFcn = 'trainlm';  % Levenberg-Marquardt backpropagation. 
  
hiddenLayerSize = 4; 
net = fitnet(hiddenLayerSize,trainFcn); 
  
net.input.processFcns = {'removeconstantrows','mapminmax'}; 
net.output.processFcns = {'removeconstantrows','mapminmax'}; 
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net.divideFcn = 'dividerand';  % Divide data randomly 
net.divideMode = 'sample';  % Divide up every sample 
net.divideParam.trainRatio = 90/100; 
net.divideParam.valRatio = 10/100; 
net.divideParam.testRatio = 0/100; 
  
net.performFcn = 'mse';  % Mean Squared Error 
  
net.plotFcns = {'plotperform','plottrainstate','ploterrhist', 'plotregression', 'plotfit'}; 
  
% Train the Network 
[net,tr] = train(net,Input_std_peak,Conc_std); 
  
% Test the Network 
y = net(Input_std_peak); 
e = gsubtract(Conc_std,y); 
performance = perform(net,Conc_std,y) 
  
% Recalculate Training, Validation and Test Performance 
trainTargets = Conc_std .* tr.trainMask{1}; 
valTargets = Conc_std .* tr.valMask{1}; 
testTargets = Conc_std .* tr.testMask{1}; 
  
% Deployment 
% Change the (false) values to (true) to enable the following code blocks. 
if (true) 
    genFunction(net,'PeakANN'); 
    y = PeakANN(Input_std_peak); 
end 
  
Conc_Pred_peakANN = PeakANN(Input_Validation(i,:)') .* y_sigma + y_mu]; 
MSE_peakANN = immse(Conc_Exp,Conc_Pred_peakANN);  
B.2.3 Principal component regression (PCR) 
CompNum = 8; 
[PCALoadings,PCAScores,PCAVar,mu] = pca(Input_fit); 
betaPCR = regress(Conc-mean(Conc), PCAScores(:,1:CompNum)); 
betaPCR = PCALoadings(:,1:CompNum)*betaPCR; 
betaPCR = [mean(Conc) - mean(Input_fit)*betaPCR; betaPCR]; 
  
Conc_Pred_PCR = [ones(n,1) Input_Validation]*betaPCR; 
MSE_PCR = immse(Conc_Exp,Conc_Pred_PCR); 
B.2.4 Principal component analysis + Artificial neural network 
[Input_std_pcaANN, X_mu, X_sigma] = zscore(Input_peak(:,locs));  
[Conc_std, Y_mu, Y_sigma] = zscore(Conc);  % standardization 
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trainFcn = 'trainlm';  % Levenberg-Marquardt backpropagation. 
  
hiddenLayerSize = 4; 
net = fitnet(hiddenLayerSize,trainFcn); 
  
net.input.processFcns = {'removeconstantrows','mapminmax'}; 
net.output.processFcns = {'removeconstantrows','mapminmax'}; 
  
net.divideFcn = 'dividerand';  % Divide data randomly 
net.divideMode = 'sample';  % Divide up every sample 
net.divideParam.trainRatio = 90/100; 
net.divideParam.valRatio = 10/100; 
net.divideParam.testRatio = 0/100; 
  
net.performFcn = 'mse';  % Mean Squared Error 
  
net.plotFcns = {'plotperform','plottrainstate','ploterrhist', 'plotregression', 'plotfit'}; 
  
[net,tr] = train(net,Input_std_pcaANN,Conc_std); 
  
y = net(Input_std_pcaANN); 
e = gsubtract(Conc_std,y); 
performance = perform(net,Conc_std,y) 
  
trainTargets = Conc_std .* tr.trainMask{1}; 
valTargets = Conc_std .* tr.valMask{1}; 
testTargets = Conc_std .* tr.testMask{1}; 
  
if (true) 
    genFunction(net,'pcaANN'); 
    y = PcaANN(Input_std_pcaANN); 
end 
  
Input_Validation_pca = (Input_Validation-mu)*PCALoadings(:,1:CompNum); 
Conc_Pred_pcaANN = pcakANN(Input_Validation_pca) .* y_sigma + y_mu]; 
MSE_pcaANN = immse(Conc_Exp,Conc_Pred_pcaANN); 
 
B.2.5 Partial least squares regression (PLSR) 
CompNum = 8; 
[~,~,~,~,betaPLS] = plsregress(Input_fit,Conc,CompNum); 
Conc_Pred_PLS = [ones(n,1) Input_Validation]*betaPLS; 
MSE_PLS = immse(Conc_Exp,Conc_Pred_PLS); 
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Appendix C. PCR and PLSR 
Principal component regression (PCR) is a regression analysis technique based on principal 
component analysis (PCA), which is one of the most popular methods for multicollinearity 
elimination and dimensionality reduction. The reason for converting a high-dimensional 
dataset to a low-dimensional one is to reduce the amount of calculation and the chance of 
model overfitting. Dimensionality reduction through PCA is accomplished by orthogonal 
linear transformation, which can transform a series of linearly related variables into a set 
of linearly uncorrelated new variables. These orthogonal variables, also called principal 
components, are the linear combination of the original variables. They keep the data feature 
with minimum loss of information. PLSR also created the new variables, namely 
components, for model fitting. However, the components in PCR are not correlated with 
the response variable, whereas PLSR does consider the response variables when 
constructing the components. 
The PCR steps for a case that has 𝑛 experimental data and 𝑝 variables are shown below: 
1. Normalizing each variable by subtracting its mean, so that the average of each 
column in data matrix 𝑋(𝑛 × 𝑝) is zero; or standardizing each variable by 
subtracting its mean and then dividing the standard deviation. Standardization can 
be implemented by ‘zscore’ function in Matlab. 
2. Calculating the covariance matrix 𝐶 (𝑝 × 𝑝) of the normalized or standardized data 
matrix (𝑛 × 𝑝). 
3. Calculating the eigenvalues and unit eigenvectors of the covariance matrix 𝐶, and 
then performing a descending sort for the eigenvalues and their corresponding 
eigenvectors in matrix 𝐸 (𝑝 × 𝑝). 
4. Choosing 𝑚 principal components and then reducing the dimension of original data 
from (𝑛 × 𝑝) to (𝑛 × 𝑚) by multiplying the first 𝑚 columns of 𝐸 (𝑝 × 𝑝). 
5. Regressing the dependent response (𝑛 × 1) on the principal components with the 
low-dimensional data matrix (𝑛 × 𝑚) . 
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